













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 








The Functional Role of HCMV miRNAs 
Jonathan Andrew Pavelin 
 
Thesis presented for the degree of  
Doctor of Philosophy 









I declare that the research and analysis presented in this thesis is my own 
unless otherwise stated. This work has not been submitted for any other degree 
and this thesis was composed entirely by myself. 
 
 





miRNAs are a species of small-regulatory RNA that post-transcriptionally 
regulate gene expression via the RNA induced silencing complex (RISC). They 
are encoded ubiquitously among animals and plants, and have recently been 
shown to be encoded by the majority of herpesviruses. It seems likely that 
herpesvirus encoded miRNAs have evolved as a tool for the manipulation of 
host-cellular and viral-gene expression during infection. 
Human cytomegalovirus (HCMV) is a clinically important herpesvirus that 
represents a significant cause of morbidity and mortality in the immune-
compromised. HCMV encodes as many as 25 miRNAs during infection, but the 
function of the majority of these is not known. 
Identifying the targets of HCMV miRNAs will not only establish a basis for 
understanding the role of miRNAs within the context of HCMV infection, but 
also provide a means for discovering novel host-virus interactions. Using RISC 
immunoprecipitation and siRNA screening, host-cellular targets of viral miRNAs 
that play important roles in the biology of HCMV were identified. ATP6VOC, a 
key component of the vacuolar-ATPase, was shown to be a target of miR-US25-1 
and subsequent siRNA knockdown of ATP6VOC resulted in the almost complete 
inhibition of infectious virion production. Despite this, ATP6VOC knock-down 
did not inhibit viral entry, DNA synthesis, or gene expression, highlighting a 
possible role for ATP6VOC in the assembly and egress of HCMV. 
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A critical step in HCMV assembly and egress is the formation of the juxtanuclear 
virion assembly compartment (VAC). The HCMV VAC is derived from host-
cellular endocytic and secretory vacuoles, and is crucial for the efficient nuclear 
egress of nucleocapsids, cyotplasmic tegumentation, final envelopment, and the 
egress of mature virions. Using siRNA knock-down, immunofluorescence-
microscopy, and western-blot analysis, a crucial role for ATP6VOC and 
v-ATPase function in the formation of the VAC was demonstrated. siRNA knock-
down of ATP6VOC resulted in a failure in the reorganisation of trans-golgi and 
early-endosomal compartments during infection, resulting in a failure in VAC 
formation. 
These findings demonstrate a crucial role for ATP6VOC during infection, and in 
so doing identify a novel host factor that is required for HCMV assembly.
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1.1. Human Cytomegalovirus 
Herpesviridae is a family of large DNA viruses that infect fish, birds, and 
mammals. Over 100 herpesviruses have been identified to date and they share a 
number of key morphological, genetic, and biological features [1-3]. 
Herpesviruses are structurally and functionally complex. The herpesvirus 
genome consists of a large linear double-strand of DNA between 110 kb to 
240 kb [1]. Viral DNA replicates in the host cell nucleus, facilitated by a 
combination of host and viral encoded proteins, and is loaded into an 
icosohedral nucleocapsid before traversing the nuclear membrane [4-8]. Once 
in the cytoplasm, the nucleocapsid is surrounded by a plethora of tegument 
proteins that possess a multitude of functions ranging from viral assembly to 
host immune suppression [9-13]. Finally, herpesviruses are enclosed in a host 
acquired lipid envelope prior to egress, containing a variety of viral 
glycoproteins that are critical for the binding and entry of progeny virus [14-
17].  
Within the host, herpesviruses typically infect a wide variety of cells and tissues 
during acute infection (with several notable exceptions, eg. Epstein Barr virus), 
and then establish a lifelong persistent, latent infection in specific cell types 
[18]. 
Based on species specificity, host cell tropism, and genome content the 
Herpesviridae have been further divided into three distinct sub-families (α, β, 
and γ). Of these, 8 are known to infect humans, (Human herpes virus 1-8). 
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Human herpes virus 5, more commonly known as HCMV, is the prototypical 
human β-herpesvirus [2, 3, 18]. 
HCMV is a clinically important pathogen. It is readily transmissible and infection 
is prevalent in populations worldwide with infection rates of >95% of adults in 
developing countries, and <30% of adults in the USA and western Europe [19-
23]. Acute infection with HCMV is frequently asymptomatic in immune-
competent individuals, although may be associated with mild 
mononucleosis-like symptoms. Despite a robust immune response, the host fails 
to completely clear HCMV, and the virus remains latent in a sub-population of 
cells, likely within the myeloid lineage. The clinical consequences within the 
immune-competent are thought to be minor, although it has been suggested 
that the disease burden of HCMV persistence may have links to cancer and 
immune-senescence in the elderly [24-26]. In immune-compromised 
individuals, HCMV acute infection and reactivation from latency represents a 
global healthcare burden and is a significant cause of morbidity and mortality 
worldwide [18]. 
 26 
1.2. Clinical manifestations 
HCMV is capable of infecting a wide range of host cell types during acute 
infection. HCMV is transmitted via infected body fluid, typically urine or saliva, 
and is able to infect fibroblast, epithelial, endothelial, mesenchymal, 
macrophage, and smooth muscle cells in vivo, causing widespread infection of 
the liver, lung, kidney, pancreas, retina, and gastrointestinal tract [19, 27-29]. 
Despite the broad tropism of primary HCMV infection, acute infection is 
typically asymptomatic in the immune-competent, and is rapidly cleared by the 
host innate and adaptive immune response. 
HCMV represents a significant cause of morbidity and mortality of immune-
compromised hosts in whom it is capable of causing severe disease. These 
include individuals with acquired immune deficiency syndrome (AIDS), allograft 
recipients, and neonates. 
Individuals co-infected with HCMV and HIV experience a loss of CD4+ 
lymphocyte adaptive immune function with the progression of disease which 
can cause the reactivation of lytic HCMV replication and systemic, acute 
infection in these individuals. This can result in severe disease, including colitis, 
retinitis, oesophagitis, and encephalitis [19, 22, 30-32]. These conditions are a 
significant contributor to morbidity and mortality in end-stage AIDS patients. 
HCMV acute infection and reactivation represent significant hurdles to the 
success of solid organ transplants. Transplant recipients receive powerful 
immune-suppressive drugs in order to prevent host vs graft disease. This leads 
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to an increase in susceptibility to the risk of acute CMV disease in these 
individuals, either by reactivation or by de-novo infection. Chronic HCMV 
infection is thought to contribute directly to vascular disease and inflammation 
in kidney, heart, and liver grafts and this leads to a heightened risk of organ 
rejection [19, 33-35]. Estimates put HCMV chronic infection as contributing to 
the failure of between 5% and 20% of all solid organ transplants [19, 35].  
Finally, HCMV infection in neonates is the leading cause of congenital birth 
defects in the developed world, affecting as many as 2% of live births [19, 36]. 
Both the transient and permanent outcomes of intra-uterine infection can be 
severe. Intrauterine infection of newborns can occur as a result of reactivation 
in HCMV positive mothers, or more commonly, as a result of primary infection 
of HCMV naive mothers. Approximately 10% of neonates that contract HCMV in 
utero are symptomatic at birth, with a further 15% developing symptoms in 
later life. Transient outcomes of infection include growth retardation, 
pneumonitis, hepatomegaly, splenomegaly, and seizures. Permanent outcomes 
include motor disabilities, mental retardation, hearing and vision loss, seizures, 
and death. The fact that this disease typically occurs as a result of primary 
infection of naive mothers means that this is of particular concern in developed 
countries, where the likelihood of mothers being HCMV naive is much higher 
than in developing countries [36]. 
Despite historical and more recent efforts, attempts at developing an effective 
HCMV vaccine has not been successful and this is due in part to the complexity 
of host-virus interactions during infection [37-39]. In terms of licensed 
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therapeutics for the treatment of acute HCMV infection, clinicians have several 
options; ganciclovir, valganciclovir, foscarnet, and cidofovir. However, the side 
effects of these treatments can be severe, and resistant strains quickly arise in 
subjects treated with these drugs [40, 41].   
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1.3. HCMV genome organisation and strain variability 
The HCMV genome is approximately 240 kb in length, and this is the largest 
among herpesviruses. The genome structure of HCMV is distinct from other 
β-herpesviruses. The HCMV genome consists of two unique regions: Unique 
Long (UL); Unique Short (US), which, unlike other β-herpesviruses, are each 
flanked by terminal and internal repeats: Terminal Repeat Long/Internal 
Repeat Long (TRL/IRL) and Terminal Repeat Short/Internal Repeat Short 
(TRS/IRS). Throughout these regions, genes are distributed across the genome 
in both orientations, and each gene has been designated sequentially based on 
genomic location. Similar to other herpesviruses, this genomic location has no 
apparent bearing on expression kinetics during infection [18]. 
Thanks to the annotation of HCMV genome sequences and the advent of 
bacterial artificial chromosome (BAC) technology, it has been possible to 
generate genetically homogenous virus preparations for several strains, which 
is critical in functional studies of HCMV and host cell biology during infection 
[42]. However, HCMV has the capacity to readily adapt to its host. This 
adaptability extends to cell-culture, and repeated passage of HCMV has resulted 
in polymorphisms in these experimental strains which need to be taken account 
in studies of HCMV infection. HCMV strains can be broadly divided into two 
categories: high passage laboratory adapted strains, and low passage clinical 
strains. Some lab adapted strains, such as AD169 and Towne, were initially 
conceived as potential vaccine candidate strains and obtained by serial passage 
of clinical isolates in fibroblasts. Due to favourable growth kinetics, and the ease 
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of creating high titre cell free virus stocks, AD169 in particular has been widely 
adopted for in vitro experimentation. However, this adaptation for growth in 
fibroblasts has resulted in regions of the HCMV genome being permuted. 
Compared to low passage CMV isolates, both AD169 and Towne have large 
deletions (22 and 19 ORFs, respectively) and have a variety of sense and non-
sense mutations throughout the genome [15, 43-45]. As such, low passage 
strains of HCMV such as Merlin, and TR are important for studies in epithelial 
and endothelial cells in vitro, and should be used to supplement 
experimentation using lab adapted strains to rule out strain specific artifacts 
[42, 46]. A middle ground has been established with the isolation of the TB40 
virus strain, which was established by high passage of clinical isolates on 
endothelial and fibroblast cells, and selected for broad tropism in vitro [47]. BAC 
derived TB40 is more intact genetically compared with other lab adapted 
strains, but shares many of the beneficial characteristics that makes them well 
suited for in vitro experimentation [47]. 
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1.4. The HCMV replicative cycle 
1.4.1. Entry and penetration 
HCMV binds to the surface of cells via heparan sulphate on the host cell plasma 
membrane, likely via gB and gM/gN [48-50]. Entry of the attached virion occurs 
by interaction between viral glycoprotein complexes gH/gO/gL (trimer) or 
gH/gL/UL128-131 (pentamer) with host cell receptors, which facilitate fusion 
of the viral envelope with the plasma membrane, or triggers endocytic uptake of 
the virion, respectively [14, 45]. Entry into endothelial and epithelial cells relies 
on the pentamer complex and occurs in a low pH dependent manner via 
endocytosis [44]. Entry into fibroblast cells relies predominantly on the trimer 
complex and is pH independent [48]. Penetration of the cytoplasm, therefore, 
occurs either immediately post entry in fibroblast cells, or upon fusion of the 
viral envelope with the endocytic membrane in endothelial and epithelial cells. 
The mechanisms at play and the role of tegument proteins in the trafficking of 
the HCMV capsid to the nuclear membrane have not been well characterised. 
However, in HSV-1 infection several roles have been ascribed to tegument 
proteins that have orthologues in HCMV. The HSV1 protein UL36 (orthologous 
to HCMV UL48) is responsible for the trafficking of capsids along the 
microtubule network. UL48 has been shown to be critical for HCMV immediate 
early (IE) gene expression, so it may be that the roles of these proteins are 
similar [51-53]. HSV1 protein UL25 (orthologous to the critical gene HCMV 
UL77 [51, 54]) has been shown to be important in the delivery of viral genomes 
to the nucleus [55]. Once the capsid reaches the nuclear membrane, it is not 
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clear how the HCMV genome penetrates the nucleoplasm. There is evidence of 
other herpesviruses interacting with components of the nuclear pore complex, 
and it has been shown that capsids do not enter the nucleus. As such it seems 
likely that viral proteins interact with the nuclear pore and facilitate the ejection 
of the viral DNA genome into the nucleoplasm [56]. However, the specific viral 
and host-cellular machinery involved in this process are not known for HCMV. 
1.4.2. HCMV gene expression and DNA replication and packaging 
The HCMV genome is in the region of 240 kb in length and encodes 
approximately 200 canonical ORFs [57]. However, recent analysis of the HCMV 
transcriptome has raised the possibility that the protein coding capacity of the 
HCMV genome might far exceed this estimate via non-canonical translation 
from upstream ORFs, alternative splicing, and anti-sense transcription, although 
these observations have not yet been validated [3, 46, 58]. 
Once the viral genome is unpackaged in the nucleus, HCMV gene expression 
takes place in a temporal cascade that can be simplistically divided into three 
categories; immediate early (IE), early, and late [59]. Transcription of the viral 
genome is dependent on host-cellular RNA polymerase II in addition to 
transcription factors such as IE72 and IE86 for the generation of viral RNA 
species, including mRNAs, miRNAs, and lncRNAs [58, 60]. 
Transcription of the UL122-123 major immediate early region encodes an 18 kb 
transcript that produces several distinct mRNA species. This includes mRNAs 
for the immediate early proteins IE72 and IE86 which act synergistically to 
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activate the expression of host-cellular transcription factors, and viral 
transcription factors that together facilitate the initiation of the lytic viral gene 
expression cascade [61-64]. Immediate early events activate the expression of 
early and delayed early gene expression and these genes encode proteins 
critical for viral DNA replication such as: UL54 the DNA polymerase; UL44 the 
DNA processivity factor; UL57 the single stranded DNA binding protein; and 
UL70/102/150 the helicase-primase complex. Other important early genes that 
have been characterised have roles in manipulating the host immune response: 
US2, US3, US6, and US11 interfere with MHC class I presentation; UL83, 
TRS1/IRS1, US2, and US3 circumvent the cellular response to IFN-α -β -γ 
stimulation; UL111A, UL146, UL33, UL78, US27, and US28 mimic chemokines or 
chemokine receptors to inhibit cell mediated immunity and the inflammatory 
response [65, 66]. Finally the late genes, which depend on the expression of IE 
genes and the initiation of viral DNA replication, encode the majority of the 
structural proteins and those involved in assembly and maturation of the HCMV 
virion [18, 60]. 
Replication of the viral DNA genome is primarily facilitated by virus encoded 
machinery, with a viral DNA polymerase, processivity factor, and helicase 
synthesised early in infection. Initiation of viral DNA replication is dependent on 
the circularisation of the parent DNA, and proceeds bi-directionally in a rolling 
circle, producing concatemers which are inverted and cleaved prior to 
packaging into nucleocapsids [18, 51]. The 162 capsomeres that make up the 
HCMV nucleocapsid consist primarily of the major capsid protein (UL86), 2 
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copies of the minor capsid protein (UL48-49), and 1 copy of the minor capsid 
binding protein (UL46) [67]. Cleavage of the newly synthesised genome and 
packaging into the capsid occur in concert, via the activities of UL89, UL56, and 
UL51, through the UL104 portal protein [67-69]. 
1.4.3. Nuclear egress 
While still in the nucleus the nucleocapsid becomes partially tegumented, 
acquiring proteins such as pp150 [70, 71]. Egress of the nucleocapsid through 
the nuclear membrane is thought to occur via the activity of the nuclear egress 
complex, consisting of UL50/UL53 which span the inner nuclear membrane, and 
UL97, a kinase that phosphorylates host nuclear protein Lamin A/C. Together 
these proteins act to destabilise the inner nuclear membrane [5, 6, 67, 72]. It is 
not entirely clear how the nucleocapsid traverses the inner nuclear membrane 
and escapes the outer nuclear membrane to penetrate the cytoplasm, but it is 
likely to occur by a similar method to that seen in HSV1. In HSV1, the 
nucleocapsid traverses the inner nuclear membrane, and acquires a primary 
envelope in the process. The capsid then passes through the perinuclear space, 
the envelope fuses with the outer nuclear membrane, and the naked capsid 
egresses to the cytoplasm [73]. However, the viral and host proteins involved in 
HCMV nuclear egress remain elusive. 
1.4.4. HCMV assembly, and egress 
Secondary tegumentation and acquisition of the final envelope occurs in a 
juxtanuclear occlusion of host-cellular membranes that forms the virion 
 35 
assembly compartment (VAC). The HCMV VAC is derived from host-cellular 
trans-golgi and endosomal compartments, the markers of which colocalise with 
viral tegument proteins and glycoproteins at late stages during infection [74-
77]. The process of final envelopment also appears to occur within the VAC, and 
egress may occur via multivesicular bodies [78-80]. 
The viral tegument proteins have diverse functions at time-points both pre- and 
post-immediate early gene expression. These functions include: apoptosis 
regulation (UL36, UL38); immune evasion (UL83 [pp65], IRS1/TRS1, UL82 
[pp71]); capsid trafficking (UL32 [pp150]); DNA release from the capsid (UL47, 
UL48); activation of gene expression (UL35, UL82 [pp71], US24); nuclear export 
of unspliced mRNAs (UL69); and virion assembly (IRS1/TRS1, UL32 [pp150], 
UL99 [pp28]) [11]. Studies have shown that many of these tegument proteins 
are not explicitly required, although only pp65 and UL36 are entirely 
dispensable for replication in vitro. Several of these proteins are essential to 
HCMV replication and these include pp150, UL48, UL77, UL94, and pp28. 
Characterising the functions of tegument proteins in vitro has proven difficult as 
they frequently perform multiple roles throughout the replicative cycle. 
Functional roles have typically been ascertained by performing deletion and 
complementation analyses and this makes secondary roles of tegument proteins 
at late time-points difficult to resolve [11-13, 81].  
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1.5. HCMV latency 
Despite a robust immune response in infected individuals, the host is not able to 
completely eradicate HCMV infection, and HCMV persists in the host by 
establishing latency in specific cell types. In these latently infected cells, the 
HCMV gene expression program is restricted and the gene expression cascade 
does not progress as in lytic infection. The viral genome is maintained in the 
absence of virion production, and is able to initiate the lytic gene expression 
program in response to certain stimuli [82-84].  
The factors that are required for the establishment and maintenance of HCMV 
latency have not been well characterised and the sites of HCMV latency in vivo 
have not been definitively identified. This is due to a combination of several 
factors: an inability to study the virus within the natural host; the lack of a 
representative animal model; and the lack of consistency between observations 
in ex vivo latently infected cells and in vitro models of latency. 
A definitive confirmation of the site of latency can be made when a) cells from 
naturally infected hosts can be shown to latently carry virus, b) these cells can 
be stimulated to induce the reactivation of lytic gene expression, c) these cells 
support de novo infection, and d) the virus can establish latency in these cells 
after de novo infection. Viral genomes have been isolated from several tissue 
types from HCMV sero-positive, but otherwise healthy donors, indicating that 
these cell types may be sites of HCMV latency in vivo.  
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Low copy numbers of HCMV genomes and viral antigens have been detected in 
endothelial and smooth-muscle cells isolated from otherwise healthy 
individuals, indicating that these cell types might represent an important site of 
HCMV latency, and possibly persistence [83, 85, 86]. However, other studies 
were unable to detect HCMV in endothelial and smooth-muscle cells from 
saphenous tissue from triple bypass patients, indicating that physical location 
within the host may also play a role in the establishment of latency in these cell 
types [87]. HCMV positive cells have also been isolated from bone marrow 
stroma from healthy donors, and these cells were able to support productive 
infection [88]. Bone marrow stroma is a heterogenous tissue, containing 
multiple cell types, including myeloid lineage cells. Myeloid lineage cells seem 
likely to represent an important reservoir of HCMV latency [85, 89]. CD14+ 
myeloid precursors isolated from healthy donors contain low copy numbers of 
viral genomes, and critically, viral replication can be reactivated as a result of 
differentiation of these cells ex vivo [85, 89, 90]. 
The majority of cultured cells that can be infected experimentally do not 
become latently infected. However, an experimental latency model has been 
established in naive CD34+ myeloid precursor cells in vitro. These cells have the 
pluripotent potential to give rise to many of the cell types from which latent 
HCMV has been recovered in vivo. Evidence put forward by several groups have 
put forward a model that CD34+ cells represent the major site of latent carriage, 
and that differentiation to terminal cell fates can stimulate the reactivation of 
HCMV viral replication [82, 83, 87, 91]. If this is the case it has still not been 
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established why all lineages that are derived from CD34+ precursors do not 
carry latent HCMV genomes. It may be that latent carriage of HCMV limits 
pluripotent potential, forcing development of these cells down specific lineages. 
These putative factors that potentially regulate the differentiation of latently 
infected stem cells remain elusive. 
Our understanding of HCMV, and other human β-herpesvirus latency is limited 
by our inability to effectively study these viruses in their natural hosts, and the 
lack of appropriate animal models that faithfully recapitulate elements of 
human infection and disease. Herpesviruses are notorious for their diversity, 
and their evolutionary divergence means that there are substantial differences 
between CMVs that infect closely related species. Despite this, we have been 
able to glean some understanding from animal homologues, such as murine 
CMV (mCMV), rat CMV (rCMV), guinea pig CMV (gpCMV), chimpanzee CMV 
(cCMV) and rhesus CMV (rhCMV). These homologues continue to be useful for 
our understanding of HCMV, but they have a number of limitations. rhCMV and 
cCMV are most similar in terms of sequence homology to HCMV, but they have 
limited use as animal models due to the expense, ethical implications, and 
restrictions on the use of primates in research. As such, most comparative 
studies utilise rodent based models. Rodent CMVs, while divergent from HCMV, 
have been useful for studying some aspects of HCMV biology. mCMV is capable 
of establishing latency in cells of the myeloid lineage, and as such has been used 
for studies of latency and reactivation. rCMV is capable of causing vascular 
disease and as such has been useful for the study of the involvement of CMV 
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infection in allograft rejection. gpCMV is capable of intrauterine transmission 
and has been used to increase our understanding of congenital CMV [92-95]. 
However, none of these models individually is able to faithfully recapitulate 
HCMV disease in humans, and the interpretation of data from experiments using 
these models is complicated by the incomplete structural and functional 
homology between genes encoded by HCMV and rodent CMVs [96]. Recently, 
several 'humanised' mouse models for HCMV have emerged. In essence, these 
models involve the xenograft of populations of HCMV infected myeloid 
precursor cells into severe combined immunodeficiency (SCID) mice. In these 
mice, HCMV can establish latency in transplanted monocytes and macrophages, 
which disseminate throughout the mouse into numerous organ tissues. 
Crucially, HCMV is capable of then reactivating in these tissues [97, 98]. The 
potential to study latent and lytic HCMV infection in human cells within the 
context of a systemic infection represents a promising avenue for future studies 
of all aspects of HCMV biology in vivo. 
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1.6. miRNAs and the RNA induced silencing complex (RISC) 
The HCMV genome encodes a multitude of miRNAs, and although our functional 
understanding of their roles in infection is in its infancy, the fact that miRNA 
coding capacity is retained across the Herpesviridae is suggestive that they play 
an important role in herpesvirus biology. 
miRNAs are a small RNA species between 21 and 24 nucleotides in length, that 
are capable of regulating gene expression. They were originally identified as 
novel developmental regulators in the nematode Caenorhabditis elegans. The 
lin-4 gene in C. elgeans encodes an miRNA that negatively regulates lin-14 gene 
expression by binding to the 3'UTR of the mRNA. This results in a temporal 
decrease in lin-14 expression which is critical in the development of the worm 
[99-101]. Initially considered somewhat of a novelty, they are now known to be 
ubiquitously expressed in animals and plants, and their effect on the regulation 
of gene expression is widespread. For example, in humans, over 60% of mRNAs 
are predicted to be regulated by miRNAs [102]. 
The majority of mature miRNAs are transcribed as primary transcripts 
(pri-miRNAs) by RNA polymerase II. These transcripts are typically in excess of 
1 kb in length, and form multiple hairpin structures by Watson-Crick base 
pairing [103]. These hairpins are recognised and cleaved by the RNase-III 
endonuclease, Drosha, to form precursor transcripts (pre-miRNAs), which are 
then processed in the cytoplasm by the components of the RISC. The pre-miRNA 
is bound by TRBP (a double strand RNA binding protein) and cleaved by 
another RNase-III endonuclease, Dicer, in the cytoplasm to generate a 
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~22 nucleotide long duplex [104, 105]. The strand with the least stable 5’ end is 
loaded into Argonaute 2, a key catalytic component of the RNA induced 
silencing complex (RISC). This microRNA ribonucleoprotein complex (miRNP) 
is guided to transcripts based on sequence complementarity of the miRNA to 
the target mRNA [106]. These miRNP complexes then bring about the 
post-transcriptional down-regulation of specific target transcripts via the 
activity of RISC [107-109].  
miRNP complexes bring about translational repression in a number of ways. 
Exact complementarity to the miRNA seed sequence results in Ago-2 mediated 
mRNA cleavage. This type of regulation of transcription is common in plants, 
but in animals the majority of miRNAs do not share exact complementarity with 
their target transcripts, and target recognition is driven by a motif known as the 
seed sequence. This seed sequence consists of the 5' nucleotides of the miRNA 
between positions 2 and 8, and these are a strong predictor of miRNA targeting. 
Despite this, interactions frequently occur via mis-matches in the seed region 
and with interaction between miRNA and mRNA outside of the seed region 
[110].  
miRNA regulation of target transcripts is frequently associated with mRNA 
decay, which is independent of Ago-2 mediated cleavage [102, 110, 111]. 
Current evidence points to this being a result of miRNP mediated translational 
repression, via recruitment of RNA helicases eIF4A2 and DDX6, and subsequent 
de-adenylation of the mRNA, rendering the mRNA vulnerable to degradation by 
exoribonucleases in the cell [112]. 
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Target sites for miRNAs were initially thought to lie exclusively within the 
3'UTRs of host transcripts [101]. However, recent advances in miRNA target 
identification has allowed for extensive mapping of targets sites by deep 
sequencing, and it appears that miRNAs frequently regulate transcripts via 
target sites in the 3'UTR, CDS, and 5'UTR, and individual miRNAs exhibit 
targeting bias to specific regions of transcripts . 
The emerging role of miRNAs in mammalian gene expression is that of a 
micromanager; fine tuning the levels of the majority of transcripts in the cell to 
maintain an optimal protein mileu. As such, the majority of individual 
miRNP:mRNA interactions bring about marginal changes in target transcript 
levels [102, 110, 111, 113, 114]. However, there are also scenarios where the 
impact of miRNA regulation can have a more profound effect. The redundant 
nature of miRNA;mRNA interactions means that individual miRNAs, can target 
multiple transcripts within biological pathways, and multiple miRNAs can 
regulate individual transcripts [115, 116].  
This can make the field of miRNA research especially challenging; traditional 
loss or gain of function studies result in either marginal phenotypes due to the 
minor effect of an individual miRNA on transcript levels, or no phenotype due to 
the inherent redundancy in eukaryotic pathways. 
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1.7. The identification of miRNAs and their targets  
1.7.1. miRNA identification 
The identification of miRNAs is the first step in characterising their biological 
role, and represents a foundation of miRNA research. Initial techniques utilised 
a combination of biochemistry and bioninformatics to identify novel miRNAs, 
and these approaches have become more complex as high-throughput next 
generation sequencing techniques have been developed. There are several 
hurdles to the identification of novel miRNAs by biochemical methods that arise 
from their intrinsic biological properties. Their short length, functional 
redundancy, and low levels of expression mean that these techniques can lack 
sensitivity. As such, increasingly complex bioinformatic prediction algorithms 
have become an important tool in miRNA discovery. 
Biochemical methods for miRNA discovery can be divided into three categories; 
forward genetics, miRNA cloning, and next-generation sequencing. Initial 
studies in Caenorhabditis elegans used phenotype driven forward genetics 
approaches to identify lin-4 and let-7 miRNAs. These miRNAs were knocked out 
in nematodes, and this resulted in defective developmental phenotypes which 
were subsequently identified to be the result of defective down-regulation of 
lin-14, and lin-41/57, respectively [100, 101, 117, 118]. These phenotype driven 
approaches proved extremely time consuming, expensive, and laborious owing 
to the effort required to identify the genes responsible for a given phenotype. 
This goes some way to explain the seven year gap between the identification of 
the first and second miRNA in C. elegans. A significant step forward was made 
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with the approaches that allowed for the cloning of small RNAs from cDNA 
libraries [119]. This process involves extracting total RNA, and fractionating 
these RNAs by size using polyacrylamide gel electrophoresis (PAGE). Linkers 
are then ligated to these small RNAs, allowing for reverse transcription, PCR 
amplification, and sequencing. It was these approaches that first allowed for the 
identification of miRNAs in viruses, animals, and plants [120-122]. Although this 
technique is undoubtedly powerful, it has limited sensitivity as small RNA 
species isolated by this technique are skewed towards those that are highly 
expressed, and it is not able to detect miRNAs that are expressed under specific 
biological conditions. These liabilities have been somewhat circumvented by the 
development of next-generation sequencing approaches which have massively 
increased the sensitivity of small RNA sequencing approaches, allowing for the 
reliable genome wide identification of miRNAs [123]. 
Bioinformatic approaches have been at the forefront of efforts to annotate novel 
miRNAs in animals and plants. These bioinformatic tools vary in complexity, but 
in essence all share the ability to annotate miRNAs based on structural criteria 
from observed miRNAs, with varying sensitivities [124]. Early methods relied 
on the conservation of pre-miRNA stem loop structures to annotate putative 
miRNAs in closely related species (such as MiRScan and MiRseeker). These tools 
proved extremely useful in early studies in Caenorhabditis and Drosophila [125, 
126]. However, they are relatively insensitive as they are unable to identify 
divergent miRNA sequences. These shortcomings led to the development of 
evermore sophisticated tools that are able to annotate miRNAs using complex 
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algorithms that predict the RNA structural features of pre-miRNAs. Tools such 
as ProMIR use machine learning approaches that are able to designate criteria 
that differentiate miRNA encoding stem-loops by comparing them to a dataset 
of random stem loops from throughout the genome, the majority of which do 
not encode miRNAs. After candidate stem loops are identified, a series of 
restriction criteria are applied in order to identify pre-miRNAs. These include 
structure, sequence composition, sequence conservation, thermodynamic 
stability, and structural conservation [127]. Despite the stringency of these 
criteria, these methods still identify many stem loop structures that don't 
encode miRNAs, and they require a positive dataset with a sufficient number of 
validated miRNA sequences in order to confidently identify novel sequences. 
Together, bioinformatic and biochemical approaches have led to the 
identification of 24521 putative miRNA loci from 206 species encoding 30424 
mature miRNAs, according to the last update of the miRBase miRNA sequence 
repository [128]. 
1.7.2. miRNA target identification 
A major focus within the field of miRNA research has been the identification of 
target transcripts. Seed sequence complementarity is a strong predictor of 
miRNA:mRNA interactions and as such several bioinformatic tools have been 
conceived that are capable of predicting these canonical interactions. These 
include miRanda [129], mirSVR [130], PicTar [131], TargetScan [132], 
TargetScanS [133], RNA22 [134], PITA [135], DIANA-microT [136], and 
RNAHybrid [137]. These computational approaches apply different criteria to 
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identify targets. Sequence complementarity, binding energy, target site 
accessibility, and evolutionary conservation are among the restriction criteria 
employed. However, it is now clear that a large proportion of miRNA regulation 
occurs via non-canonical interactions with target transcripts, and these are very 
difficult to predict [110]. As such the relevance of these tools is currently under 
review within the field. Indeed, analyses of the efficacy of these target 
prediction algorithms when compared with validated target data, have 
estimated the false positive rate for the most sophisticated algorithms at 
50-70% [113, 138]. This renders these tools unsuitable for systematic screens 
of miRNA targets. However, these tools continue to be extremely useful in 
identifying canonical target sites when combined with biochemical analyses 
that directly identify the targets of miRNAs. 
With inherent flaws in the bioinformatic prediction of miRNA targets, 
techniques that allow for the unbiased identification of miRNA:mRNA 
interactions are critical. There are several techniques available to researchers 
that allow for the direct identification of miRNA target transcripts that vary in 
their complexity, but share a similar basic premise. These techniques utilise the 
miRNP complex in order to pull-down miRNAs and their target transcripts 
which can then be isolated and analysed by high-throughput transcriptome 
analyses. The simplest of these techniques is RISC immunoprecipitation (RISC-
IP or RIPCHIP). In RISC-IP miRNP complexes are isolated by 
immunoprecipitation via antibodies against components of RISC, or molecular 
tags on components of RISC or transfected miRNAs , which allows for the 
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isolation of a population of RNAs that are enriched for the targets of miRNAs. 
These RNA samples can then be analysed using microarray, and compared to 
total RNA to ascertain which transcripts are targeted by miRNAs [139, 140]. An 
evolution of this technique are high-throughput RNA sequencing by cross-
linking and immunoprecipitation (HITS CLIP) and photo-activatable 
ribonucleoside CLIP (PAR CLIP). These techniques cross-link miRNPs to their 
target mRNAs using UV radiation prior to immunoprecipitation, which prevents 
any post-lysis interactions and enables the identification of unstable or 
transient target interactions. Given the stability of these cross-linked complexes 
it is also possible to RNAse digest transcripts allowing for the identification of 
the region which contains the target site by deep sequencing [141, 142]. A 
further evolution of this is the cross linking and sequencing of hybrids (CLASH) 
technique, which employs a molecular ligation step to fuse miRNAs to their 
target mRNAs. This creates a hybrid miRNA:mRNA molecule, representing the 
candidate miRNA ligated to the binding site of the mRNA. In this way CLASH 
allows for the direct identification of target transcripts, the candidate miRNA 
that is responsible for targeting, and the target sites within these transcripts by 
deep sequencing [143]. This technique is extremely powerful in that it is able to 
reveal non-canonical interactions that would otherwise be very difficult to 
predict.  
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1.8. Viral encoded miRNAs 
miRNAs represent a powerful biological tool for micro-managing the cellular 
environment. As such, it is particularly interesting that several virus families 
have been shown to encode miRNAs. Adenovirus, torque-teno virus, and 
polyomavirus family members encode miRNAs in their DNA genomes, and 
several retroviruses encode miRNAs in their RNA genomes [144-147]. However, 
the vast majority of viral miRNAs identified to date are encoded by 
herpesviruses (93% [432/463]), including HCMV which encodes as many 25 
mature miRNAs from 15 precursors [128, 148].  
Despite the conservation of this capacity to encode miRNAs, miRNA sequence 
conservation is not observed between herpesvirus family members (with the 
exception of the EBV and rhesus lymphocryptovirus, and human and chimp 
CMV) [128, 149, 150]. However, as we learn more about herpesvirus miRNAs 
targets it is becoming clear that there may be functional conservation or 
convergence within the family, with orthologous miRNAs regulating the same 
genes or distinct miRNAs regulating genes within related pathways [151-154]. 
It also interesting to note that viral encoded miRNAs are predominantly 
associated with viruses capable of lifelong persistence or latency. During 
latency, the viral genome must be maintained in a restricted state, yet still 
responsive to external stimuli that allow for lytic reactivation, all without being 
detected by the immune system. The ability of the virus to manipulate the host 
cell despite severe restriction of the viral gene expression program is crucial. In 
theory, miRNAs represent a 'weapon of choice' for this type of low profile 
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regulation of host-cellular and viral gene expression during latency. Individual 
miRNAs are capable of regulating multiple transcripts within diverse cellular 
pathways, making them genetically economic. Critically, miRNAs can do this 
without eliciting an immune response, as there is no known pattern recognition 
receptor that can differentiate viral from host transcribed miRNA, meaning that 
they are likely non-immunogenic.  
The identification and functional characterisation of herpesvirus miRNA targets 
is still in its infancy and as such their role is not entirely clear. Despite this, there 
is an emerging picture from functional studies to date that miRNAs facilitate 
lytic replication and maintain latent persistence in a number of ways: 
manipulating the host cell innate immune response; manipulating host cell 
processes to facilitate virus replication; manipulating virus gene expression 
cascade; and mimicking host cell miRNAs to drive proliferation.  
1.8.1. Herpesvirus miRNAs facilitate innate immune evasion 
There are several examples of herpesviruses using miRNAs to manipulate 
cell-mediated innate immune responses in the host. Natural killer (NK) cells are 
an important component of the innate immune response to viral infection, and 
circumventing the killing of infected cells by NK cells is a well utilised strategy 
for viruses to persist [155-157]. As such, it is interesting that activating ligands 
for NK cells are conserved targets of herpesvirus miRNAs. HCMV encoded 
miRNA UL112-1, KSHV miRNA K12-7, and EBV BART-2-5P regulate the 
expression of MHC class I related-sequence B (MICB) during lytic and latent 
infection [151-153]. MICB encodes a natural killer (NK) cell activating ligand, 
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which activates cytolytic NK activity, resulting in the killing of infected cells. 
Herpes virus miRNAs can also regulate the inflammatory response to sites of 
infection. HCMV miR-UL148D-1 can regulate CCL5, which encodes RANTES, a 
secreted chemokine that attracts leukocytes to sites of inflammation and also 
has a role in signaling for the proliferation and activation of NK cells [158]. 
Clearly, tempering NK cell cytolytic activity and inhibiting the inflammatory 
response are desirable during lytic replication, and during latency may facilitate 
the survival of persistently infected cells. 
Apoptosis is another well utilised innate immune response to viral infection 
[159]. Multiple pathways in the cell detect cell stress associated with viral 
infection and initiate programmed cell death to eradicate infected cells. KSHV 
miR-K10a contributes to circumventing this response by regulating the 
expression of tumour necrosis factor like weak inducer of apoptosis receptor 
protein (TWEAKR) during latent infection [160]. TWEAK signaling induces 
caspase activation and apoptosis, as well as the induction of pro-inflammatory 
cytokine expression, both of which are important components of the host innate 
immune response. Another regulator of apoptotis, Bcl associated factor-1 
(Bclaf1), is regulated by HCMV miR-UL112-1 and KSHV miRs-K12-5, -9, -10a, 
and 10b during lytic HCMV infection, and lytic and latent KSHV infection [161, 
162]. The exact role of Bclaf1 in infection is not clear. It has reported pro- and 
anti-apoptotic functions, and has been shown to be required for T-cell activation 
[163]. In HCMV infection, Bclaf1 prevents the accumulation of IE1 expression at 
early time-points as part of the cell's innate restriction of viral infection. As 
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such, it is possible that down regulation of Bclaf1 is important to de-repress IE 
expression in latently infected cells. Indeed, observation that miRNA regulation 
of Bclaf1 facilitates lytic reactivation in KSHV suggest that this might be the case 
[161, 162, 164].  
1.8.2. Herpesvirus miRNAs manipulate host cell gene expression to create 
an environment conducive with replication during the lytic cycle 
Herpesvirus miRNAs have also been shown to manipulate the cellular 
environment in order to facilitate viral genome replication and viral assembly 
during lytic replication. HCMV miR-US25-1 regulates cell cycle regulator cyclin 
E2 (CCNE2) and RNA polymerase II transcriptional regulator TRIM28 during 
infection [165]. HCMV manipulation of the cell cycle has been well documented, 
with cell cycle arrest at the G1/S phase boundary creating optimal conditions in 
the host cell for the replication of the viral genome and generation of progeny 
virus [166, 167]. At early time-points in infection, HCMV induces CCNE2 
expression, which is then down-regulated by miR-US25-1 at late time-points. It 
may be that un-checked cyclin E expression throughout virus replication would 
disrupt this favourable host-cellular environment. TRIM28 encodes a 
component of a transcriptional co-repressor complex that is able to inhibit viral 
gene expression [168, 169], and recent observations have demonstrated that 
TRIM28 mediates RNA polymerase II pausing and progression at intrinsic sites 
in the genome [170]. Interestingly, HCMV encoded UL79 performs a similar role 
in the transcription of the viral genome by RNA polymerase II. It is plausible 
that UL79 confers a distinct functionality to RNA polymerase II that is critical to 
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HCMV genome transcription, and competition with TRIM28 could be 
deleterious [171]. 
Perhaps the most dramatic role identified to date for herpesvirus miRNAs 
during lytic infection is the coordinated regulation of multiple endocytic 
pathway genes during HCMV infection which are required to facilitate assembly. 
miRs-US5-1, -US5-2, and -UL112-1 down-regulate VAMP3, RAB5C, RAB11A, 
SNAP23, and CDC42 to facilitate the aggregation of endocytic compartments to 
form the VAC, and this is critical for the production of functional virions [172]. 
Interestingly individual knockout of these miRNAs had marginal effects on viral 
phenotype, with the defect in the formation of the VAC only apparent after 
knockout of all of these miRNAs. This study is ground breaking as it 
demonstrates that viral miRNAs have evolved to regulate the expression of 
multiple genes within complex biological pathways to facilitate a crucial process 
in the viral replication cycle. It also highlights that the importance of regulation 
of individual miRNA targets may not be apparent when considered in isolation, 
due to redundancy in miRNA regulation. 
1.8.3. Herpesvirus miRNAs restrict the viral lytic gene expression 
program 
One strategy employed by herpesviruses to maintain latency is the restriction of 
the immediate-early viral transactivators by targeting either viral or host-
cellular transcription factors. The ability to restrict the lytic gene cascade by 
direct miRNA mediated regulation of viral transcriptional transactivators 
appears to be conserved in herpesviruses and conceivably has a role in both the 
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establishment and maintenance of latency: HCMV encoded miR-UL112-1 targets 
IE72; HSV1 miR-H2-3p and HSV2 miR-III target ICP0; KSHV encoded miR-K12-
5, 7-5p, -9 , EBV encoded BART6-5p, and OHV-2 miR-5 regulate the expression 
of ORF50 (RTA). In HSV1, HSV2, KSHV,  EBV, OHV-2 these miRNAs are 
expressed during experimental latency, and it seems that these miRNAs likely 
act to restrict the lytic cycle, and subdue reactivation of lytic infection during 
latency [173-180]. 
Host-cellular transcription factors are also important in the initiation of viral 
lytic gene expression. In KSHV latency, ORF50, which encodes the RTA protein, 
is down-regulated by NFkB expression [181]. NFkB expression is typically 
inhibited by IkBa expression. However, during KSHV latency miR-K12-1 down-
regulates IkBa expression, which results in the de-repression of NFkB thus 
facilitating the restriction of ORF50 [182]. Similarly another NFkB antagonist, 
nuclear factor I/B (NFIB) is regulated by KSHV miR-K12-3 which down-
regulates ORF50 during latency [175]. This is another example of distinct 
miRNAs regulating the same effector via distinct intermediaries in a redundant 
fashion. 
1.8.4. Herpesvirus miRNAs mimic host-cellular miRNAs during latency to 
facilitate persistence 
γ-herpesviruses are distinct among herpesviruses possessing a well 
documented ability to promote the proliferation of latently infected cells, which 
allows the virus to spread. This transformative capability results can result in 
tumours in the host. KSHV is the causative agent of Kaposi's sarcoma and 
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associated with primary effusion lymphoma and some forms of multi-centric 
Castleman's disease, while EBV is associated with Burkitt's lymphoma, 
Hodgkin's lymphoma, and nasopharyngeal carcinoma, and MDV causes T-cell 
lymphoma in chickens.  
During normal development, host-cellular miR-155 is involved in regulating the 
development and differentiation of lymphatic cells and aberrant over-
expression of miR-155 is associated with lymphoproliferative cancers. 
Interestingly, γ-herpesviruses appear to disrupt the miR-155 axis in order to 
facilitate the proliferation of latently infected cells. KSHV encodes a miR-155 
functional orthologue, miR-K12-11, which shares many targets of miR-155 in 
B cells in vitro [183, 184]. Significantly, miR-K12-11 expression in vivo results in 
B-cell proliferation in a humanised mouse model and is able to rescue defective 
B-cell phenotypes associated with miR-155 knockout [185, 186]. MDV also 
encodes a miR-155 functional orthologue, miR-M4, and this has provided a rare 
opportunity to examine the consequences of the regulation of multiple host-cell 
transcripts by conserved herpesvirus miRNAs within the context of a natural 
host. Observations for miR-M4 function showed similarity in function to 
miR-K12-11, with a miR-M4 knock-out exhibiting a reduction in transformative 
ability which could be somewhat rescued by complementation with miR-155 
[187].
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1.9. Preface: A global screen to identify the host cellular targets of HCMV 
miRNAs in acute infection1 
As a prelude to the work presented in Chapters 2, 3, and 4, preliminary 
experiments were performed to identify the host cellular transcripts that are 
targeted by HCMV encoded miRNAs. The results of these experiments are 
presented in Section 1.9.2, 1.9.3, and 1.9.4, and these findings are discussed in 
Section 1.9.5 and 1.9.6. 
1.9.1. RISC immunoprecipitation and microarray for identifying the 
targets of HCMV miRNAs in acute infection in vitro 
RISC immunoprecipitation (RISC-IP) is a powerful biochemical technique for 
identifying the targets of miRNAs. During miRNA mediated gene regulation, 
target transcripts are stably associated with RISC. Using antibodies or molecular 
tags on miRNAs or RISC, it is possible to immunoprecipitate miRNPs allowing 
for the isolation of target transcripts [139, 140]. As such this technique was 
selected for use in this screen. As discussed in Chapter 1.3 the AD169 strain has 
been widely adopted by the research community and has proved a useful tool 
for the study of HCMV. However, serial passage has led to the deletion of 22 
ORFs that are not required for replication in fibroblast cells, most notably in the 
genome region between UL128 and UL150 [44, 57, 188]. Of particular relevance 
for this study, this region is known to encode a single miRNA, HCMV 
miR-UL148-D1. Therefore, in order for this screen to be representative, it was 
                                                        
1 Data presented in this section were from experiments performed in their entirety by Finn Grey 
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crucial to include a genetically competent strain of HCMV. The low passage 
clinical strain TR was therefore also used in this screen in order to circumvent 
any potential bias resulting from strain dependent variation in miRNA 
expression. 
Fibroblast cells were infected with AD169 or TR at an MOI of 3, and lysates were 
harvested at 72 hours post infection (hpi). Three separate pools of RNA were 
then isolated from these lysates. Total RNA was isolated to ascertain total 
transcript abundance, and two immunoprecipitated RNA fractions were 
isolated: a specific RISC pull down using an Ago2 antibody; and a pull down 
using pre-bleed serum as a control for non-specific binding. In order to establish 
a baseline which allowed for transcripts targeted by host-cellular miRNAs to be 
discounted, identical RISC-IPs were performed on lysate from uninfected 
fibroblast cells. For each RNA sample, the abundance of over 24000 transcripts 
were analysed using the Illumina HumanRef-8 microarray platform. 
In order to specifically identify the targets of viral miRNAs from the microarray 
data, a series of calculative steps were required (Figure 1.1). In brief, this 
calculation enabled the identification of transcripts that were proportionally 
over represented in the infected RISC-IP sample when compared with the 
uninfected RISC-IP sample, taking into account a) virus induced transcriptional 




Step 1: Normalise against viral induced host cell gene regulation 
Enrichment = (IP RNA/Total RNA) 
This calculation took into account the global changes in host-gene expression 
that take place during HCMV infection [167]. 
Step 2: Normalise against non-specific pull-down in IP samples 
Corrected Enrichment = (Enrichment-[Pre bleed IP/Total RNA]) 
A second calculation was performed to control for non-specific pull-down of 
transcripts by subtracting the enrichment values from the pre-bleed IP from 
those using the Ago2 antibody. 
Step 3: Normalise against transcripts targeted by host-cellular miRNAs 
Corrected Infected Enrichment - Corrected Uninfected Enrichment 
Finally, a calculation was performed to normalise against host-cellular miRNA 
target transcripts in the RISC-IP sample.
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Figure 1.1 Example of enrichment calculation from RISC-IP and 
microarray 
Examples of calculations for ATP6VOC, a genuinely enriched transcript from the 
screen, and PSG6, a false positive that was corrected by normalising against the 
pre-bleed serum IP enrichment value. 
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1.9.2. RISC-IP and microarray: AD169 versus TR 
The data from RISC-IP and microarray are summarised in Figure 1.2. Over 96% 
of transcripts in AD169 infected fibroblast cells and 98% in TR infected 
fibroblast cells were not enriched by RISC-IP compared with the negative 
control IPs, which was consistent with the hypothesis that viral miRNAs 
regulate the expression of a specific subset of host-cellular genes during 
infection. Enrichment levels were as high as 28 fold in the AD169 infected 
RISC-IPs, and 19 fold in the TR infected RISC-IPs compared with the negative 
control IPs (Figure 1.2 A and B and Table 1.1). The distribution of enrichment 
values for the top 50 transcripts demonstrated that, overall, higher levels of 
enrichment were observed in AD169 infected fibroblast cells compared with TR 
infected fibroblast cells. This is likely a result of AD169 being capable of 
reaching higher titres in cultured fibroblast cells than TR, which results in a 
higher abundance of miRNAs [44]. Despite these differences, of the 686 unique 
transcripts identified in AD169 infected fibroblast cells and 442 transcripts in 
TR infected fibroblast cells that were enriched over 2 fold by RISC-IP, 222 of 
these transcripts overlapped (Figure 1.2D). This overlap was statistically 
significant (p=<0.001 by chi-squared test), and provided a high degree of 




Figure 1.2 Distribution and overlap of normalised enrichment values in AD169 and TR infected fibroblast cells 
A. Distribution of fold enrichment in AD169 infected fibroblast cells (N=1). B. Distribution of fold enrichment in TR infected 
fibroblast cells (N=1). C. Distribution by gene rank and fold enrichment of the top 50 transcripts in AD169 and TR infected 
fibroblast cells. D. Overlap of transcripts enriched over 2 fold between AD169 and TR infected fibroblast cells. Fibroblast cells 
were infected with AD169 or TR at an MOI of 3, and at 72 hpi cell lysates were obtained. RNA was fractioned, and RISC-IP 
performed. Total RNA, RISC-IP RNA and control-IP RNA were extracted and analysed by microarray. 
Note: The sum of the values in Figure 1.2A and B do not match the values in D (in Figure 1.2A and B, 729 and genes are 
enriched over 2 fold, where as the value is 686 in Figure 1.2B). This is the result of the duplication of specific probes for 

























































































1.9.3. RISC-IP and microarray: Choosing targets of interest from the 
screen 
The RISC-IP and microarray provided nearly 700 transcripts that are potentially 
regulated by HCMV miRNAs during infection. Prior to this study, others had 
used similar approaches and observed that highly enriched transcripts were 
more likely to be genuine targets of viral and host-cellular miRNAs [189, 190]. 
As such, an assumption was made that transcripts with higher levels of 
enrichment represented targets with a higher probability of being significantly 
regulated by HCMV miRNAs during infection, and these transcripts were 
deemed to be of particular interest. 
Due to the higher levels of enrichment in the AD169 infected RISC-IPs and the 
minimal strain dependent variation between RISC-IP datasets (Table 1.1 and 
Figure 1.4), the AD169 strain was chosen for further study. The 30 most highly 
enriched putative targets in AD169 infected fibroblast cells are summarised in 
Table 1.1. 
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Table 1.1 Summary of top 30 transcripts from RISC-IP in AD169 and TR 
infected fibroblast cells  
Gene ID AD169 TR Definition 
ATP6V0C 28.9 9.8 ATPase, H+ transporting, lysosomal  
GRN 22.8 2.4 granulin  
COMMD10 14.3 19.9 COMM domain containing 10  
CTRB2 13.3 6.4 chymotrypsinogen B2  
SGSH 12.8 3.4 N-sulfoglucosamine sulfohydrolase  
LGALS3 10.9 3.6 galactoside-binding, soluble, 3 (galectin 3)  
PIGH 9.9 3.7 phosphatidylinositol glycan anchor biosynthesis  
BSG 9.0 1.7 basigin  
LEPRE1 7.2 2.4 leucine proline-enriched proteoglycan  
LIN28B 7.1 2.9 lin-28 homolog B  
SRPRB 7.0 3.8 signal recognition particle receptor  
PDIA5 6.6 4.2 protein disulphide isomerase family A  
CCNE1 6.1 5.7 cyclin E1  
FLJ39061 6.1 3.2 FLJ39061  
NUCB1 6.0 0.9 nucleobindin 1  
PRSS8 6.0 4.6 protease, serine, 8  
BCKDHA 5.9 1.8 branched chain keto acid dehydrogenase E1  
C1ORF35 5.9 4.7 chromosome 1 open reading frame 35  
TMEM74 5.7 2.4 transmembrane protein 74  
NUCB2 5.6 3.1 nucleobindin 2  
DSC2 5.5 2.0 desmocollin 2  
FALZ 5.2 2.1 fetal Alzheimer antigen  
CCNE2 5.2 2.6 cyclin E2  
STX10 5.1 3.5 syntaxin 10  
COL1A1 5.0 3.4 collagen, type I  
KRTAP10-7 4.9 4.1 keratin associated protein 10-7  
FAM38A 4.9 2.3 family with sequence similarity 38  
ACP2 4.7 1.8 acid phosphatase 2, lysosomal  
ATP1A3 4.7 4.2 ATPase, Na+/K+ transporting  
PROK2 4.7 4.4 prokineticin 2  
Source: Appendix Table 7.1 and Table 7.2.  
 
To identify the miRNAs responsible for targeting the transcripts identified by 
RISC-IP, the bioinformatic tool RNAHybrid was used [137]. Seed sequence 
complementarity was analysed within the 3'UTR, ORF, and 5'UTR of the top 30 
targets from the AD169 RISC-IP, for the 14 HCMV miRNAs most abundant 
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during infection [150]. These data are summarised in Figure 1.3. HCMV miRNA 
seed complementarity was found for 27 out of 30 of the putative targets. 
Interestingly, the majority of the miRNA target sites were located in the ORF of 
transcripts with only 14 of 30 predicted to target the 3'UTR. Until recently it 
was assumed that cellular miRNA targeting was tightly restricted to the 3'UTRs 
of transcripts [133]. However, a recent study has debunked this assumption, 
and demonstrated directly that miRNA target sites are distributed across 5'UTR, 




Figure 1.3 Bioinformatic target prediction for the 14 most abundant HCMV miRNAs against the top 30 putative target 
transcripts identified by RISC-IP and microarray in AD169 infected fibroblasts 
5'UTR, ORF, and 3'UTR sequences for the top 30 putative targets of HCMV miRNAs were analysed for seed-sequence 
complementarity (with sequence constraint between nucleotide 1-7 and 2-8) against the 14 most abundant HCMV miRNAs. 
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1.9.4. RISC-IP and micro-array: AD169 vs  miR-US25-1 
Prior to these studies in infected cells, RISC-IPs had been performed using 
individual miRNAs outside of the context of infection. HEK-293 cells were 
transfected with a biotinylated miRNA mimic or a plasmid expressing HCMV 
miR-US25-1, and immunoprecipitations were performed using myc-tagged 
Ago-2 or via the biotin tag [165]. As a high proportion of the most highly 
enriched targets identified from RISC-IP in AD169 infected cells (8/30) were 
predicted to be targeted by miR-US25-1, the results of these RISC-IPs were 
compared to the AD169 infected dataset to determine whether there was any 
correlation. These datasets are presented in full in Appendix Table 7.3, and a 
summary of the overlap with the top targets from the infected RISC-IPs is 
presented in Figure 1.4. Of the top 30 targets from the AD169 and miR-US25-1 
RISC-IPs, 6 out of 30 overlapped (Figure 1.4B). With the exception of LGALS3, 
all of these targets had high confidence predicted target sites for HCMV miR-
US25-1, including ATP6VOC, the most highly enriched target transcript from 
AD169 RISC-IP and second most highly enriched transcript from the TR RISC-IP 
(Figure 1.3). 
miR-US25-1 is one of the most highly expressed HCMV miRNAs during infection 
[150]. Assuming that miRNA abundance is likely to be proportionally associated 
with target transcript regulation, miR-US25-1 represented a particularly 
relevant focus for further study. 
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Figure 1.4 Overlap between top targets in AD169 and miR-US25-1 RISC-IP pull downs (AD169 N=1; TR N=1; bUS25-1 
N=2; pUS25-1 N=2) 
A. Heat map showing enrichment levels of 30 top targets from AD169 and TR infected RISC-IPs, biotinylated miR-US25-1 
pull-downs, and myc-Ago pull downs in 293s expressing miR-US25-1. 
B. Venn diagram showing overlap between the 30 top transcripts from AD169 and the consensus of the miR-US25-1 RISC-IPs. 
A B 
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1.9.5. Comparison of putative HCMV miRNA targets to other herpesvirus 
miRNA target studies 
Relatively few host-cellular transcripts have been identified as targets of HCMV 
miRNAs (as discussed in Chapter 1.8) [152, 158, 172, 191]. The few that have 
been identified have been shown to regulate innate immune pathways, 
transcription, and endocytosis. 
 miR-UL112-1 targets MICB, which is an MHC-class 1-like ligand required for the 
activation of natural killer (NK) cells [152]. miR-UL-148D-1 targets RANTES, a 
TNFα and IL-1α stimulated pro-inflammatory chemotactic cytokine, that is 
involved in the recruitment of immune cells to sites of infection [158]. BclaF1, a 
transcription factor that restricts HCMV replication, is dynamically regulated 
during infection, first by viral proteins delivered in the tegument, and at later 
time-points by miR-UL112-1 [191]. Most recently, miR-UL112-1, US5-1, and 
US5-2 have been shown to target multiple factors within the endocytic pathway 
[172]. 
MICB and the majority of the endocytic genes identified by Hook et al were 
enriched in the AD169 and TR RISC-IPs, giving additional confidence in the 
validity of this screen. BclaF1 was not enriched, but this could be due to the 
relatively late time-point of miR-UL-112 regulation of BclaF1 [191]. RANTES 
was also not enriched and this may be a result of strain or cell line dependent 
variation in miRNA targeting [158]. 
 68 
It is particularly interesting that of the top 30 targets identified by RISC-IP in 
HCMV infected fibroblast cells, only CCNE2 has been identified as being 
dysregulated during HCMV infection (as a prelude to the work presented here 
[165]). Looking more broadly at pathways that one would predict viral miRNAs 
to regulate, only 3 of the top 30 candidates have been identified as having roles 
in immunity; BSG, GRN and LGALS3. BSG encodes basigin (a.k.a. CD147), a 
member of the immunoglobulin superfamily that may have roles in IL-8 
production [192]. GRN encodes granulin, which has recently been shown to act 
as a chaperone for unmethylated CpG DNA, which acts as an agonist for TLR9 
signaling, and down stream NFkB gene expression [193]. LGALS3 encodes 
galectin-3, a member of a family of galactoside binding proteins that regulates 
the innate immune response [194, 195]. It is feasible that down-regulation of 
each of these transcripts could be beneficial to HCMV replication.  
Several transcripts identified in the screen (ATP6VOC, TMEM74, STX10, and 
ACP2) have functions within the endocytic and exocytic pathways [196-198], 
which is particularly interesting in light of recent findings by Hook et al [172]. 
These findings are considered in greater detail in Chapter 4.1. This leaves the 
majority of the targets identified in the screen (23/30) that have not been 
shown to have roles in infection, and several of which are poorly characterised 
in the literature. 
In other miRNA encoding human herpesviruses, there have been a small 
number of systematic studies of the host-cellular targets of viral miRNAs, with 
few targets identified, and even fewer validated targets identified to date [199-
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203]. Of the high confidence targets that have been identified in these studies, 
there is no overlap with the high confidence HCMV miRNA targets that were 
identified in this screen. This is not particularly surprising, as there is little 
conserved miRNA sequence homology between human herpesvirus family 
members. However, there is some evidence of functional homology in miRNA 
targeting across Herpesviridae. Membrane trafficking processes have been 
implicated as a target of viral miRNA regulation from systematic analyses of 
KSHV and EBV, although the functional role of this regulation is currently 
unknown [202, 203]. Similarly, the results presented here from RISC-IP in 
HCMV infected fibroblast cells, and observations by Hook et al suggest that 
membrane trafficking processes may also be an important target of HCMV 
miRNAs. It may be that membrane trafficking processes play an important role 
in herpesvirus biology. 
1.9.6. Caveats in the interpretation of RISC-IP data: Technical and 
analytical shortcomings of RISC-IP and microarray 
The RISC-IP technique is a powerful tool for the systematic screening of miRNA 
targets, and has proven useful in the field of viral miRNA target analysis [139, 
140, 203, 204]. Procedurally, it is far less complex and time consuming 
compared to other biochemical techniques, such as HITS-CLIP, PAR-CLIP, and 
CLASH. The efficiency of the pull-down means that less input material is 
required, which is highly advantageous when analysing infected cells. Also, 
microarray data are quicker and easier to interpret compared to deep 
sequencing data. However, the RISC-IP and microarray do have several inherent 
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shortcomings that need to be accounted for when interpreting data from 
screens using these methods.  
Potential sources of false positives 
One shortcoming is that the process for obtaining input material for the 
immunoprecipitations involves cell lysis, and this has the potential for creating 
associations between miRNAs and transcripts that are normally segregated by 
physical barriers within the cell, creating false positives for interactions that do 
not take place within the context of cell biology [205]. Other techniques 
circumvent this by cross linking miRNPs prior to cell lysis, which prohibits post 
lysis mRNA:miRNP interactions [110, 141, 142]. 
One major benefit of the RISC-IP method is the efficiency of the pull-down, 
which is beneficial for obtaining large amounts of RISC associated transcripts 
from a small input volume. However, this is associated with a relatively low 
stringency in RISC-IP (similarly in HITS/PAR CLIP) when compared to CLASH. 
In CLASH it is possible to use multiple wash steps under denaturing conditions 
to remove non-specific RISC associated transcripts. As such, the likelihood for 
false positives as a result of these non-specific interactions is increased in 
RISC-IP. However, efforts were made in this screen to mitigate this effect, with 
Ago2 IPs normalised against total RNA and pre-bleed serum IPs (as described in 
Chapter 1.9.1). 
Within the context of HCMV infection, there are further considerations to be 
made when interpreting the data from RISC-IP. It is possible that several 
host-cellular miRNAs may be up-regulated during infection. Similarly, there is a 
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possibility that changes in the host-cellular gene expression mileu during 
infection might result in the stabilisation of specific transcripts that are targeted 
by host-cellular miRNAs. Both of these scenarios would specifically increase the 
abundance of these transcripts which has the potential to create false positive 
enrichment. 
Potential sources of false negatives 
The requirement of a stable interaction between RISC and target transcripts in 
RISC-IP means that transcripts that do not stably associate with miRNPs can not 
be identified by this method. A large proportion of these targets are likely to be 
those that are rapidly degraded by RISC due to exact miRNA:mRNA sequence 
complementarity. While this type of targeting is relatively common in plants, it 
accounts for only a small proportion of the miRNA regulated 'targetome' in 
mammals [206], and the majority of predicted host-cellular targets do not share 
exact complementarity with viral miRNAs [141, 172, 200-202, 207]. As such, 
while not discounting the possibility, one would assume that the majority viral 
miRNA target transcripts are not regulated in this way, and as such the screen 
presented here is still likely to be largely representative. 
Also of note, using microarray as a platform for the analysis of the RISC-IP 
samples has its shortcomings. False positives and negatives can arise due to 
erroneous annotation, or cross reactivity of gene specific probes within the 
array. Finally, unlike next generation sequencing data, microarray data is 
restricted by the probes that are included on the chip. 
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1.10. Hypothesis and overall aims 
HCMV is a clinically important human pathogen, capable of causing severe 
disease in the immune-compromised and in neonates [30, 32]. It has also been 
implicated in other chronic disease processes and it may be that HCMV 
persistent or latent infection imparts a lifelong burden on the immune system of 
infected individuals [24, 25, 33]. Therapeutic options for the prevention and 
treatment of HCMV infection are limited and despite concerted efforts there is 
no vaccine available [37-41]. This highlights the requirement for the 
establishment of a greater understanding of the vastly complex interactions that 
take place between HCMV and the host during infection, with the scope for 
development of novel therapeutics for HCMV infection greatly increasing as our 
knowledge of host-virus interactions improves. 
The discovery of HCMV encoded miRNAs adds another layer of complexity to 
the conundrum of virus-host interactions during HCMV infection. These 
regulatory small RNAs have the capacity to broadly manipulate the 
transcriptional landscape within the infected cell. However, we are only 
beginning to understand the potentially far reaching roles that miRNAs play in 
HCMV biology. The identities of the vast majority of HCMV encoded miRNA 
targets are unknown, and the function that the regulation of these genes play 
within the context of infection is unclear. In order to obtain a complete 
understanding of the virus -host interactions that occur during HCMV infection 
it is critical that we first elucidate the host-cellular targets of HCMV encoded 
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miRNAs. Once these targets are identified, it will then be possible to 
characterise their functional role during infection. 
Here, it is hypothesised that HCMV miRNAs have evolved to regulate host-
cellular genes that are crucial for HCMV biology. Using a combined approach of 
miRNA target analysis and phenotypic screening of these targets, the aim of the 
work presented in this thesis was to identify and characterise the host cellular 
targets of HCMV miRNAs during infection. 
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2. Validating the top host-cellular targets of HCMV 
miRNAs  
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2.1. Chapter 2: Hypothesis and aims 
The results of the systematic screen of the host-cellular targets of HCMV 
miRNAs (Chapter 1.9) provided nearly 700 transcripts enriched >2 fold, which 
may be regulated during infection. Of the top 30 transcripts identified in 
infected fibroblast cells, 8 were bioinformatically predicted to be targeted by 
HCMV miR-US25-1 (Figure 1.3A), and a total of 12 were enriched in two 
independent miR-US25-1 pull downs (Figure 1.4A). It has been shown that miR-
US25-1 is expressed at high levels during lytic infection [150, 208]. As such, it 
was hypothesised that the regulation of host-cellular transcripts by miR-US25-1 
may be particularly important in HCMV biology.   
As discussed previously, analysing viral miRNAs in isolation may not be an 
effective strategy for characterising host-cellular targets due to inherent 
redundancy in eukaryotic pathways and miRNA targeting. In support of this 
hypothesis, several transcripts identified in Chapter 1.9 were predicted to be 
targeted by multiple miRNAs during infection (Figure 1.3) and several targets 
may have redundant functionality within the same biological pathways 
(Table 1.1). If these interactions were to be taken out of the context of infection, 
understanding the functional role of the regulation of these transcripts may be 
difficult, if not impossible. To this end, miRNA knockout viruses were used to 
validate the targets of miR-US25-1 within the context of infection. 
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The aims of the work presented in this chapter were to: 
1. Validate the enrichment of the top HCMV miRNA targets identified by 
RISC-IP and microarray. 
2. Confirm the regulation of putative target transcripts at the RNA and 
protein level. 
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2.2. HCMV miR-US25-1 regulates the expression of multiple host-
cellular transcripts during infection at an RNA level2 
Using bacterial artificial chromosome (BAC) mutagenesis two mutants of AD169 
were created which lacked the expression of miR-US25-1 (Chapter 6.3.6).  In 
one mutant (here on in denoted AD169 25-1KO) the region encoding the 
miR-US25-1 pre-miRNA was deleted, and in the second mutant (here on in 
denoted AD169 25-1/2KO) the entire miR-US25 region was deleted from the 
pAD CRE AD169 BAC [209]. A schematic showing the miR-US25-1 region and 
the BAC mutagenesis in more detail are shown in (Figure 2.1). Viral growth 
curve analyses demonstrated that these virus strains did not exhibit any growth 
defect at a given MOI [165]. RISC-IP was performed on fibroblast cells infected 
with either wild-type AD169, AD169 25-1KO, or AD169 25-1/2KO, or mock 
infected. Immunoprecipitated RNA and total RNA fractions were isolated and 
reverse transcribed. The abundance of the transcripts of interest was 
ascertained by qRTPCR using gene specific primer probe assays (Table 6.1). 
Enrichment of each transcript of interest was calculated by using the ΔΔct 
method, and was normalised to GAPDH [210]. An example of the ΔΔct 
calculation is provided in Figure 2.2. 
                                                        
2 The AD169 miR-US25-1KO mutant virus was generated by Finn Grey, and the AD169 miR-
US25-1/2KO mutant virus was generated by Natalie Reynolds. RISC-IP was performed by 
Natalie Reynolds and Jon Pavelin. 
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Figure 2.1 Schematic of BAC mutagenesis strategy for the generation of miR-US25-1 KO and miR-US25-1/2 KO strains of 
AD169. 
The miR-US25-1 and miRUS25-1/2 regions were deleted from the pAD CRE AD169 BAC as described in Chapter 6 [209]. 
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Figure 2.2 RNA levels of putative miR-US25-1 target transcripts in 
HEK-293 cells transfected with miR-US25-1 (20 nM) (72 hours post 
transfection) (N=2, n=2) 
 
The enrichment of the transcripts of interest are represented as a percentage of 
the enrichment in the AD169 infected sample Figure 2.3. 
Enrichment profiles for the genes of interest fell into one of three distinct 
categories: 
1. Transcripts targeted solely by miR-US25-1. 
2. Transcripts targeted by miR-US25-1 in addition to other HCMV miRNAs. 
3. Transcripts not targeted by miR-US25-1 that may be targeted by other 
HCMV miRNAs. 
Enrichment Value = 2^-([IP RNA - GAPDH] - [Total RNA – GAPDH]) 
or 
 Enrichment Value = 2-ΔΔcT = 2^-((ΔcT IP) – (ΔcT Total)) 
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Transcripts targeted solely by miR-US25-1 
The enrichment levels for ATP6VOC, CCNE2, BCKDHA and LGALS3 were high in 
the RISC-IP samples from wild-type AD169 infected fibroblast cells, indicating 
that HCMV miRNAs target these transcripts (29.8, 51.8, 4.9, and 12.8 fold over 
total RNA, respectively)(Figure 2.3). In stark contrast, the enrichment levels for 
these genes in the RISC-IP samples from AD169 US25-1KO and US25-1/2KO 
infected fibroblast cells were significantly lower when compared with those 
infected with wild-type AD169 (p=0.0039), and crucially these enrichment 
values were similar to those seen in uninfected fibroblast cells. Taken together, 
these data indicate that ATP6VOC, CCNE2, BCKDHA and LGALS3 are likely to be 
targeted solely by HCMV miR-US25-1 during infection. 
Transcripts targeted by miR-US25-1 in addition to other HCMV miRNAs 
The enrichment levels for SGSH, NUCB2, CCNE1, LEPRE1 and PIGH were high in 
the RISC-IP samples from wild-type AD169 infected fibroblast cells, indicating 
that HCMV miRNAs target these transcripts (7.5, 12.8, 29.3, 11.7, 7.2. and 22.2 
fold over total RNA, respectively)(Figure 2.3). Enrichment levels in RISC-IP 
samples from AD169 US25-1KO and US25-1/2KO infected fibroblast cells were 
lower than those observed in the wild type infected cells. However, enrichment 
levels were still significantly higher than those observed in uninfected fibroblast 
cells (p=0.0039). These data indicate that SGSH, NUCB2, CCNE1, LEPRE1 and 
PIGH are likely targeted by miR-US25-1 in addition to other HCMV miRNAs 
during infection. 
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Transcripts not targeted by miR-US25-1 that may be targeted by other HCMV 
miRNAs 
Enrichment levels for BSG, NUCB1, LIN28B, and GRN were significantly higher 
in the RISC-IP samples from wild-type AD169 infected fibroblasts when 
compared with uninfected fibroblast cells (p=0.0039 [with the exception of 
LIN28B, which is induced upon HCMV infection so is not expressed in 
uninfected fibroblast cells])(Figure 2.3). However, there was no significant 
difference observed between enrichment levels from RISC-IPs in either the 
AD169 miR-US25-1 KO or miR-US25-1/2KO infected fibroblast cells when 
compared with the wild-type AD169 infected sample indicating that miR-US25-
1 is not responsible for regulating these transcripts during infection. For BSG 
and NUCB1 this was clear, with enrichment values numerically similar in 
RISC-IP samples from wild-type AD169, miR-US25-1KO, and miR-US25-1/2KO 
infected fibroblasts cells. For LIN28B and GRN, a numerical difference was 




Figure 2.3 RISC-IP and qRTPCR against putative HCMV miRNA targets in fibroblast cells infected with AD169, 
AD169 25-1KO, or AD169 25-1/2 KO, and uninfected fibroblast cells at 72 hpi (N=2, n=6) (MOI = 3) 
* = p = <0.01 ascertained by Mann Whitney u-test; N = Number of technical replicates; n = Number of analytical replicates. 
RISC-IP was performed on fibroblast cells infected with AD169, AD169 miR-US25-1KO, or AD169 miR-US25-1/2KO viruses, and on 
uninfected cells. RNA was extracted and qRTPCR was performed using specific primer probes. Error bars represent the standard-
deviation from the mean.
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The HCMV miR-US25-1 pre-miRNA is a polycistronic transcript that gives rise to 
two other mature miRNAs that are expressed at lower levels during acute 
infection, miR-US25-2-3p and miR-US25-2-5p. In order to confirm that 
miR-US25-2-3p and miR-US25-2-5p did not contribute to the differential 
enrichment of ATP6VOC, CCNE2, BCKDHA, LGALS3, NUCB2 and SGSH observed 
in the infected pull-downs, RISC-IPs were performed in fibroblast cells 
transfected with miRNA mimics for miR-US25-1, 25-2-3p, and 25-2-5-p (20 nM) 
(Figure 2.4). As an additional control, a seed mutant miR-US25-1 was designed, 
in which 6 bases of the seed sequence were mutated (Figure 2.6B). 
The enrichment of ATP6VOC, CCNE2, BCKDHA, LGALS3, NUCB2 and SGSH in 
fibroblast cells transfected with miR-US25-1 was significantly higher compared 
with negative control siRNA transfected fibroblast cells. For each of these genes, 
the enrichment levels in fibroblast cells transfected with miR-US25-2-3p, 
miR-US25-2-5p, and the negative control siRNA were similar. 
These data demonstrated that miR-US25-1 was able to target these transcripts, 
where as miR-US25-2-3p and miR-US25-2-5p were not. As such, the differential 
enrichment observed within the context of infection was not the result of 
regulation by miR-US25-2-3p or -5P (Figure 2.4). A significantly higher level of 
enrichment was also observed in miR-US25-1 transfected fibroblast cells 
compared to those transfected with the miR-US25-1 seed mutant for all genes 
(p=0.0039). This demonstrates that the 2-8 base miR-US25-1 seed sequence is 
critical for the targeting of these transcripts. One possible exception is SGSH 
which still showed a high level of enrichment in fibroblast cells transfected with 
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the miR-US25-1 seed mutant. This may be the result of a non-canonical 
interaction between miR-US25-1 and SGSH outside of the seed region.
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Figure 2.4 RISC-IP and qRTPCR of putative miR-US25-1 targets in fibroblast cells transfected with miR-US25-1, 
miR-US25-1 seed mutant, miR-US25-2-3p, and miR-US25-2-5p miRNA mimics (20 nM) (N=2, n=6) 
* = p = <0.01 ascertained by Mann-Whitney u-test; N = Number of technical replicates; n = Number of analytical replicates. 
RISC-IP was performed on fibroblast cells transfected with miR-US25-1, 25-1 seed mutant, 25-2-3p, 25-2-5p, or a negative control 
siRNA 72 hours post transfection. RNA was extracted and qRTPCR was performed using specific primer probes. Error bars 
represent the standard-deviation from the mean.
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2.3. Luciferase assay confirms regulation of ATP6VOC and CCNE2 by 
miR-US25-13 
In order to validate that the bioinformatically predicted target sites within the 
transcripts of interest were sufficient and required for down-regulation by 
miR-US25-1, luciferase assays were performed. Regions of the ATP6VOC (ORF), 
BCKDHA (5'UTR), CCNE2 (5'UTR), LGALS3 (5'UTR), NUCB2 (5'UTR), and SGSH 
(5'UTR) containing the bioinformatically predicted target sites were cloned into 
vectors upstream of a luciferase reporter gene. These regions are described 
schematically in Figure 2.5. Approximately 500bp long regions BCKDHA, CCNE2, 
LGALS3, NUCB2, and SGSH 5’UTRs were amplified by PCR from genomic DNA 
using the oligonucleotides listed in , and cloned upstream of the firefly 
luciferase reporter gene in the pGL4 luc2 construct. The pRL® renilla luciferase 
construct was used as a control. For ATP6VOC, the region of the ORF containing 
the miR-US25-1 target site was synthesized using custom oligonucleotides as 
described in Chapter 6.3.5. For the ATP6V0C and CCNE2 seed mutant 
constructs, custom oligonucleotides were synthesized and the miR-US25-1 
target sites were replaced with BAMHI restriction sites. 
HEK 293 cells were then co-transfected with the luciferase expressing vectors 
(200 nmol) and a miR-US25-1 mimic (20 nM). 
                                                        
3 CCNE2 and CCNE2 mutant luciferase constructs were designed and cloned by Finn Grey. 
BCKDHA, LGALS3, NUCB2, and SGSH luciferase constructs were designed by Natalie Reynolds 
and the experiments were performed by Jon Pavelin. 
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In cells co-transfected with ATP6VOC or CCNE2 luciferase constructs and miR-
US25-1, luciferase expression was reduced to 31% and 38% expression, 
respectively, compared with cells transfected with the negative control siRNA 
(Figure 2.6A). In cells co-transfected with BCKDHA, LGALS3, NUCB2 or SGSH 
luciferase constructs and miR-US25-1, there was no consistent decrease in 
luciferase expression, compared with cells transfected with the negative control 
siRNA (Figure 2.6A). A luciferase construct containing an exact complimentary 
sequence to miR-US25-1 was used a positive control, and the empty luciferase 
vector was used as a negative control (Figure 2.6A). 
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Figure 2.5 Schematic representation of the bioinformatically predicted target sites of miR-US25-1 for ATP6VOC, 
BCKDHA, CCNE2, LGALS2, NUCB2, and SGSH 
miR-US25-1 target sites and binding in ATP6VOC, BCKDHA, CCNE2, LGALS3, NUCB2, and SGSH transcripts as predicted by RNA 
hybrid.  
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Based on these data, the bioinformatically predicted target sites for ATP6VOC 
and CCNE2 luciferase constructs were sufficient for the targeting of these 
transcripts by miR-US25-1, where as those predicted for BCKDHA, LGALS3, 
NUCB2, and SGSH appeared to be insufficient.  
In order to ascertain whether the bioinformatically predicted target sites for 
ATP6VOC and CCNE2 were required for knockdown of these transcripts, seed 
mutant luciferase constructs and corresponding seed mutant miR-US25-1 
mimic were created (Figure 2.6B). When the ATP6VOC and CCNE2 seed mutant 
constructs were co-transfected with miR-US25-1, luciferase expression was 
de-repressed, to 103% and 73%, respectively (3 fold and 2 fold increase in 
luciferase expression, respectively compared with the wild type ATP6VOC and 
CCNE2 luciferase constructs).  
The mutant miR-US25-1 mimic was unable to down-regulate ATP6VOC linked 
luciferase expression (103% when compared with negative control siRNA). 
Conversely, the mutant miR-US25-1 mimic was able to down-regulate ATP6VOC 
seed mutant linked luciferase expression (22% when compared to cells 
transfected with the negative control siRNA) (Figure 2.6C). 
Taken together, these findings demonstrate that the bioinformatically predicted 
target sites are both sufficient and required for the regulation of ATP6VOC and 
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Figure 2.6 Luciferase assays with constructs containing 
bioinformatically predicted miR-US25-1 target sites (N=3) 
A. Luciferase assays with miR-US25-1 against constructs expressing regions of 
ATP6VOC, BCKDHA, CCNE2, LGALS3, NUCB2, and SGSH containing predicted 
target sites. ATP6VOC or CCNE2 seed mutants, and an empty vector were used 
as negative controls. A miR-US25-1 seed match construct was used as a positive 
control. B. Schematic of ATP6VOC luciferase construct, ATP6VOC seed mutant, 
and mimic seed mutants. C. Luciferase assays with miR-US25-1 seed mutant 
mimic. HEK 293 cells were co-transfected with luciferase construct (200 nmol) 
and miRNA mimics (20 nM) using lipofectamine 2000. At 48 hours post 
transfection, cells were lysed and luciferase expression was quantified via plate 

































































































2.4. Regulation of transcripts by HCMV miR-US25-1 results in changes at 
the RNA level 
The results of the RISC-IPs confirm that the putative target transcripts are 
bound by HCMV miRNA RISC complexes. The main aim of this study was to 
identify miRNA targets actively regulated by HCMV during infection. As such, 
total transcript levels for each of the putative targets of miR-US25-1 were 
assayed in HEK-293 cells transfected with either a miR-US25-1 mimic or a 
negative control siRNA (20 nM) (Figure 2.7). Transcript levels for β-Actin and 
NUCB1 were assayed as negative controls for miR-US25-1 targeting. These data 
demonstrate that ATP6VOC, CCNE2, NUCB2, BCKDHA, and LGALS3 transcripts 
decrease in abundance as a result of miR-US25-1 activity. The transcript levels 
for SGSH increased 2 fold upon transfection with miR-US25-1, which was 
counter-intuitive based on previous data suggesting that miR-US25-1 targets 
SGSH. Total RNA data from the pUS25-1 RISC-IP showed no difference in SGSH 
expression in negative control and miR-US25-1 transfected cells, so this did not 
appear to be the result of an upstream target of miR-US25-1 (Appendix Table 
7.3). It is possible that this increase in transcript levels was a result of 
stabilisation of the SGSH transcript by the miRNP complex. However, this was 
not clear and this phenomenon requires further investigation. 
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Figure 2.7 RNA levels of putative miR-US25-1 target transcripts in 
HEK-293 cells transfected with miR-US25-1 (20 nM) (72 hours post 
transfection) (N=2, n=2) 
N = Number of technical replicates. n = Number of analytical replicates within 
each technical replicates. HEK-293 cells were transfected with miR-US25-1, or a 
negative control siRNA and RNA was harvested 72 hours post transfection. Gene 
expression was analysed by qRTPCR using specific primer probe sets. Error 
bars represent the standard-deviation from the mean.
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2.5. Regulation of transcripts by HCMV miR-US25-1 results in changes at 
the protein level 
In order to ascertain whether the targeting of host-cellular transcripts by 
miR-US25-1 resulted in an associated change in protein levels, western blot 
analyses were performed against ATP6VOC, BCKDHA, CCNE2, LGALS3, NUCB2, 
and SGSH in fibroblast cells infected with wild type AD169 or AD169 
miR-US25-1/2 KO (MOI=1) (Figure 2.8). 
Using specific antibodies against ATP6VOC, CCNE2, BCKDHA, LGALS3, NUCB2, 
and SGSH, the protein expression levels in fibroblast cells infected with either 
wild type AD169 or AD169 miR-US25-1/2 KO, and uninfected cells was assayed 
by western blot analysis. In order to confirm that bands observed in the western 
blot were specific for the genes of interest, protein samples were isolated from 
fibroblast cells transfected with specific siRNAs against ATP6VOC, BCKDHA, 
CCNE2, LGALS3, NUCB2, or SGSH, as a negative control. 
For all of the genes of interest, protein levels changed following infection with 
HCMV. ATP6VOC, CCNE2, and BCKDHA appeared to be induced upon infection 
whereas LGALS3, NUCB2 and SGSH were down-regulated. When infected with 
the AD169 miR-US25-1/2KO virus, expression levels of ATP6VOC, CCNE2, 
BCKDHA, and LGALS3 were higher compared to fibroblast cells infected with 
wild-type AD169, indicating that miR-US25-1 mediated regulation was 
responsible for changing the expression levels for these proteins (Figure 2.8). 
NUCB1 and SGSH protein levels were similar in fibroblast cells infected with 
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both wild type AD169 and the miR-US25-1KO virus. It may be that regulation of 
these genes by other HCMV processes or miRNAs obscures the effects of 
miR-US25-1 knock-out.  
These data demonstrate that miR-US25-1 mediated regulation of ATP6VOC, 
CCNE2, BCKDHA, and LGALS3 transcripts resulted in a decrease at the protein 
level during infection. 
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Figure 2.8 Western blot analysis of the host-cellular targets of 
HCMV miR-US25-1 
A. Representative western bots against putative miR-US25-1 targets. 
Fibroblasts were infected with AD169 or miR-US25-1/2 KO virus, or were 
transfected with siRNA. 72 hours post infection/transfection, cell lysates 
were harvested in laemmli buffer and western blot analyses were 
performed using specific primary antibodies, and LiCOR secondary 
antibodies.  B. Licor western blot quantification comparing wild type 
AD169 infected fibroblast cells with AD169 25-1/2KO infected fibroblast 
cells. Protein levels were quantified using LiCOR Odyssey software. Error 




The data presented here (published in Pavelin et al, PLOS Pathogens, 2013, 
Figures 4-6 [204]) validate several of the host-cellular transcripts identified in 
Chapter 1.9 as being targeted by HCMV miRNAs during infection. Furthermore, 
miR-US25-1 was identified as the candidate miRNA responsible for regulating 
several of these genes during infection. miR-US25-1 appears to be the sole 
HCMV miRNA responsible for regulating ATP6VOC, BCKDHA, CCNE2, and 
LGALS3 transcripts during infection. The bioinformatically predicted target 
sites for two of these genes, ATP6VOC and CCNE2, were validated as being 
sufficient and required for miR-US25-1 mediated regulation. Lastly, and 
critically, miR-US25-1 was shown to be capable of regulating ATP6VOC, 
BCKDHA, CCNE2, and LGALS3 expression at the RNA level outwith infection, 
and at the protein level within the context of infection. These data confirm that 
the presence of these transcripts in the AD169 and TR RISC-IP microarray 
datasets, and the subsequent RISC-IP and qRTPCR datasets, was not the result 
of post-lysis interactions between miRNPs and these transcripts. These data 
also validate that these transcripts are regulated by miR-US25-1 within the 
context of infection. 
2.6.1. Validation of targets of miR-US25-1 during infection 
Using RISC-IP in fibroblast cell infected AD169 miR-US25-1 knockout viruses, it 
was possible to validate the bioinformatically predicted targeting of 
miR-US25-1 within the context of infection for several of the transcripts 
presented in Figure 1.3; ATP6VOC, BCKDHA, NUCB2, CCNE2, and CCNE1. 
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Interestingly, miR-US25-1 appeared partly responsible for the regulation of 
several transcripts for which there were no predicted target sites; PIGH, which 
had no predicted HCMV miRNA target sites; and LGALS3, SGSH and LEPRE1, 
were predicted to be targeted by other HCMV miRNAs. LGALS3 is the most 
striking of these, as it appears to be solely regulated by miR-US25-1 during 
infection. These findings are reflective of the difficulties involved in accurately 
predicting targets of miRNAs. It has recently become apparent that canonical 
miRNA binding sites make up only 40% of all miRNA:mRNA interactions, with 
60% of interactions containing mismatched bases, bulges, and significant 
binding outside of the seed region [110]. Indeed, when the stringency of 
bioinformatic prediction was relaxed (allowing 6-mer sites, nucleotide 
mismatches, and loops), non-canonical target sites were identified within each 
of these genes (Appendix Table 7.5). 
The lack of sensitivity of bioinformatic prediction of miRNA target sites were 
also reflected in the results of the luciferase assays, where it was only possible 
to validate regulation by miR-US25-1 for ATP6VOC and CCNE2. In removing the 
regions containing the target sites for BCKDHA, LGALS3, NUCB2, and SGSH out 
of their normal context, RNA secondary structure that might facilitate miRNA 
binding to target sites may have been disrupted. Taking this into account, while 
the data presented in Figure 2.6 confirm the bioinformatically predicted target 
sites within ATP6VOC and CCNE2, they do not preclude the possibility that the 
bioinformatically predicted target sites for BCKDHA, LGALS3, NUCB2, and SGSH 
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are responsible for their regulation by miRUS25-1 within the context of 
infection. 
2.6.2. COMMD10: An example of why thorough validation of transcripts 
identified in miRNA target screens is critical 
As can be seen in Table 1.1, COMMD10 was the most highly enriched transcript 
from the TR RISC-IP and microarray, and was the third most highly enriched 
transcript from the AD169 RISC-IP and microarray. However, when validating 
this targeting using RISC-IP and qRTPCR, COMMD10 was not enriched in 
infected cells when compared to uninfected cells (Section 2.6.2). The reason for 
this discrepancy between the RISC-IP and microarray and qRTPCR was likely 
due to flaws in the microarray. As discussed in Chapter 1.9.6, incorrect 
annotation of probes or cross-hybridisation between transcripts and probes can 
be a source of false positives and negatives in microarray experiments, and this 
appears likely to have been the case here. This finding highlights the importance 




Figure 2.9 RISC-IP and qRTPCR of COMMD10 and b-Actin in fibroblast 
cells infected with AD169, AD169 25-1 KO, or uninfected cells (N=3) 
RISC-IP was performed on fibroblast cells infected with AD169, miR-US25-1KO, 
or miR-US25-1/2KO viruses, and on uninfected cells. RNA was extracted and 
qRTPCR was performed using specific primer probes. Error bars represent the 
standard-deviation from the mean. 
 
2.6.3. Implications of the regulation of the host-cellular targets of 
miR-US25-1 
As demonstrated in Figure 2.7 miR-US25-1 is responsible for changes in 
ATP6VOC, BCKDHA, CCNE2, LGALS3, NUCB2, and SGSH expression at the RNA 
level. For all of these genes except SGSH, this change resulted in a decrease in 
the abundance of these transcripts, to 20-40% when compared to a negative 
control. For SGSH, there was a consistent 2 fold increase in the levels of SGSH 
transcript in cells transfected with miR-US25-1 mimic. Taken at face value, 
while this result is counter-intuitive with regards to canonical miRNA 
regulation of transcripts, it is not unprecedented as there have been several 
examples reported of miRNA targeting resulting in the stabilisation of 
























The down-regulation of ATP6VOC, BCKDHA, and CCNE2 by miR-US25-1 at a 
protein-level during infection occurs on a backdrop of being robustly 
up-regulated in response to infection. LGALS3 protein expression, appears to be 
down-regulated during infection by other viral processes and supplemented by 
miR-US25-1 action. Both NUCB2 and SGSH are effectively down-regulated by 
viral processes during infection, and it may be that regulation of these factors by 
miR-US25-1 and other miRNAs is redundant, or may be required in different cell 
types, or under certain conditions within the cell (Figure 2.8). It could be that 
within the context of infection, the up-regulation of these factors is anti-viral 
and that their down-regulation is required for viral propagation. In order to 
assess this possibility, the function of these genes needs to be considered.  
When the changes in levels of these proteins shown in Figure 4.11 were 
compared with existing proteomics data in HCMV infected cells, the observed 
patterns are consistent for BCKDHA, LGALS3, and NUCB2 which provides 
further confidence in the findings presented in this chapter [59]. In studies of 
the host cell proteome during HCMV infection it should be noted that ATP6VOC 
and CCNE2 were not detected, and the data for SGSH were inconclusive due to 
the low number of SGSH peptides that were identified by mass spectrometry 
[59]. 
ATP6VOC 
ATP6VOC is a critical component of the vacuolar ATPase, which is responsible 
for the acidification of vacuoles within the secretory and endocytic pathways. 
Acidification of these vacuoles is crucial for the progression of the endocytic 
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pathway, and for membrane trafficking processes in the cell. It is also important 
in degradative pathways within the cell, with the activity of lysosomal 
degradative enzymes dependent on an acidic luminal pH [213]. As such it is 
conceivable that the up-regulation of ATP6VOC may result in defects in the 
entry of HCMV, subsequent penetration, and assembly of progeny virions. 
Interestingly, several other genes within the endosomal pathway have been 
shown to be regulated by other HCMV miRNAs during infection, which adds 
weight to this hypothesis [172]. 
BCKDHA 
BCKDHA encodes branched chain keto-acid dehydrogenase, an enzyme that is 
required for the metabolism of the branched chain amino acids (BCAAs); 
leucine, isoleucine, and valine. These are also known as the 'essential amino 
acids', because they cannot be synthesised de novo within the cell. Interestingly, 
BCAAs are important regulators of mammalian target of rapamycin (mTOR) 
[214]. mTOR is a key sensor of cell stress and is important in the regulation of 
innate and adaptive immune signaling. mTOR activity is also critical for the 
maintenance of host-cellular and viral gene expression during infection [215-
217]. It may be that miR-US25-1 regulation of BCKDHA feeds into maintaining 
mTOR activity, by preventing the breakdown of BCAAs and thus preventing 
amino acid starvation and the subsequent inhibition of mTOR. 
CCNE2 
CCNE2 encodes cyclin E2, a key regulator of the cell cycle. Cyclin E2 binds to 
CDK2, which in turn inhibits cyclin D, allowing for the progression of the cell 
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cycle from G1 to S phase [218]. HCMV has been shown to induce changes in the 
cell cycle during infection, and manipulates cell cycle progression in order to 
facilitate replication [219, 220]. It seems likely that HCMV first induces CCNE2 
expression, and then HCMV miR-US25-1 regulation of CCNE2 contributes to the 
block of cell cycle progression at the G1/S phase boundary. This establishes a 
cellular environment in the cell that is conducive with the replication of viral 
DNA. The data shown here recapitulate previous reports of HCMV miR-US25-1 
regulating CCNE2 during infection [165]. Interestingly cyclin E1 was also 
confirmed as being regulated by several HCMV miRNAs, including miR-US25-1. 
Cyclin E1 and E2 have redundant functionality within the cell cycle, which 
suggests that coordinated regulation of both of these genes may be required to 
effectively manipulate the cell cycle during infection. 
LGALS3 
LGALS3 encodes galectin 3, a member of a family of β-galactoside binding 
proteins that have roles in cell adhesion and transmembrane signaling. Other 
galectin family members have been shown to have both enhancing and 
inhibitory roles in pathogen entry, replication, and pathogenesis [221-224]. 
Specifically, galectin-3 has been implicated within the endosomal pathway as 
being a detector of pathogen entry induced vacuole breakdown, binding host 
ligands normally presented in the lumen of endosomes [225]. Galectin-8 has 
been shown to have a similar activity and has also been shown to be a regulator 
of autophagy [223]. There is evidence that a downstream effect of galectin-3 
knockdown is the down-regulation of pro-inflammatory cytokines [226]. It is 
plausible that miR-US25-1 might down-regulate these activities during infection 
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in order to prevent detection of HCMV and to inhibit the immune response. 
However, the role of galectin-3 in viral infection has not yet been characterised.  
NUCB2 
NUCB2 encodes nucleobindin-2, a poorly characterised protein with possible 
functions in calcium metabolism that has been identified as a biomarker for 
prostate cancer [227, 228]. A predicted family member, nucleobindin-1 was also 
identified as a target of HCMV miRNAs, raising another possibility that HCMV 
miRNAs may be regulating multiple redundant genes within biological 
pathways. 
SGSH 
SGSH encodes N-sulphoglucosamine sulphohydrolase, an enzyme that is 
required for the lysosomal degradation of heparan sulphate. Mutation of SGSH 
has been identified as the cause of Sanfilippo syndrome, a lysosomal storage 
disorder. There are no reports of SGSH being implicated in infection. However, 
the regulation of heparan sulphate is particularly relevant to HCMV infection as 
it is a key receptor that facilitates HCMV binding to the cell surface, which 
enables viral entry via viral glycoproteins interacting with the plasma 
membrane [45, 49]. As SGSH is regulated by HCMV post entry, it is possible that 
it may have another role. It may be that the degradation of heparan sulphate by 
SGSH has a role in inhibiting the release of viral ligands, which might affect MHC 
class I and class II presentation [45]. It is conceivable that this would be of 
benefit to HCMV during infection. 
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3. siRNA screening of HCMV miRNA targets identifies 
ATP6VOC as a host factor that is critical for viral 
replication 
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3.1. siRNA screen methodology 
The data presented in Chapters 1.9 and 2 reveal multiple host-cellular 
transcripts that are regulated by HCMV miRNAs during infection, several of 
which are targeted solely by HCMV miR-US25-1. In order to identify critical host 
factors for HCMV biology among these targets, a phenotype driven siRNA screen 
was conceived.  
Traditionally, virus replication is assayed by plaque analysis. However, for an 
siRNA screen of this scale this would not have been practical. The HCMV 
lifecycle is long, meaning that there are numerous time-points that require 
harvesting. Taking into account the number of replicates, and the number of 
siRNAs in the sceen, the expense of reagents and the manpower required would 
have been prohibitive. As such, a more direct approach for assaying viral fitness 
was devised. Fibroblast cells were transfected with siRNAs against the top 
targets of the HCMV miRNAs, and were infected with TB40E-eGFP, a strain of 
HCMV that constitutively expresses eGFP (here on in simply denoted TB40E), at 
an MOI of 1. Twenty-four hours later the inoculum was removed, and viral 
replication was measured over the course of infection via GFP intensity, which 
was monitored by plate reader. Genes that caused a viral phenotype when 
knocked down were validated using de-convoluted siRNA pools. 
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3.2. Hypotheses and aims 
Through millions of years of coevolution of virus and host, it is likely that HCMV 
miRNAs have evolved to regulate the gene expression of factors that are 
important to HCMV biology. In Chapters 1.9 and 2 a number of host-cellular 
targets of HCMV miRNAs were identified. Monitoring changes in viral 
replication as a result of the knock-down of these genes should identify factors 
that are critical in HCMV biology. 
The aims of the work presented in this chapter were to: 
1. Identify host-cellular targets of HCMV miRNAs that are critical in HCMV 
biology by analysing viral growth kinetics. 
2. Validate critical genes using de-convoluted pools of siRNAs. 
3. Investigate viral phenotype using plaque analysis, microscopy, and viral 
gene expression analysis. 
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3.3. Establishing the efficacy of siRNAs for use in subsequent screens 
In order to design an effective siRNA screen against viral phenotypes, it was 
critical to establish both the efficacy of the knockdown of the desired 
transcripts, and the optimum time-point post transfection to infect. To ascertain 
this, the efficacy of a selection of pre-validated commercial siRNAs was tested at 
24, 48, and 72 hours post-transfection using qRTPCR (Figure 3.1). For the 
majority of the genes tested the knock-down increased with time 
post-transfection. GRN and NUCB1 expression levels were higher at 48 hours 
than at 24 hour post transfection. This may have been due to replicative 
variability, as the margin of error at these time points was high. However, the 
variation between replicates was smallest, and the knock-down of protein 
expression was highest, at 72 hours post transfection, therefore this time-point 
was selected. 
 
Figure 3.1 Efficacy test of commercial siRNAs for use in siRNA screen 
(20 nM) (N=2, n=4) 







































Fibroblast cells were transfected with siRNAs and lysates harvested at 24, 48, 
and 72 hours post-transfection. RNA was extracted and gene expression levels 
were ascertained by qRTPCR using specific primer probes. Error bars represent 
the standard-deviation from the mean. 
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3.4. siRNA knockdown of host-cellular targets of HCMV miRNAs affects 
viral replication 
Fibroblast cells were transfected with siRNAs against the top host-cellular 
targets of HCMV encoded miRNAs (20 nM), and 72 hours later cells were 
infected with TB40E (MOI=1). Initially, the validated targets of HCMV 
miR-US25-1 were screened; ATP6VOC, BCKDHA, CCNE2, LGALS3, NUCB2, and 
SGSH.  
In phenotypic screens, redundancy within host-cellular pathways has the 
potential to mask critical interactions. As such, possible redundant co-factors 
that were identified as targets of HCMV miRNAs from RISC-IP in AD169 infected 
fibroblasts were also selected; NUCB1 and CCNE1. 
The GFP intensity over time in TB40E infected fibroblast cells transfected with 
siRNAs against ATP6VOC, BCKDHA, CCNE1, CCNE2, CCNE1&2, LGALS3, NUCB1, 
NUCB2, NUCB1&2, and SGSH is shown in Figure 3.2. The knockdown of the 
majority of these genes resulted in marginal effects on viral replication as 
measured by GFP intensity. However, ATP6VOC was a clear exception with 




Figure 3.2 siRNA screen: TB40E GFP expression profile in fibroblast cells transfected with siRNAs against the validated 
targets of miR-US25-1 (MOI=1)(20 nM)(N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection were infected with TB40E. Virus replication was 





























The screen was expanded to include the top 304 most highly enriched targets 
identified from RISC-IP in AD169 infected fibroblasts. The GFP intensity at 
144 hpi are summarised in Figure 3.3 and TB40E GFP expression profiles are 
presented in full in Chapter 7. These data demonstrate that there was little 
difference (less than 0.5 fold change) in viral replication after knock-down of 
the majority of the putative miRNA targets.  
An arbitrary threshold of +/- 1.5 fold of the GFP intensity of fibroblast cells 
transfected with negative control siRNA was set for identifying induction or 
inhibition of viral replication. Four genes inhibited HCMV replication when 
knocked down: ATP6VOC, NUCB1, GRN, and PRSS8, and two genes induced 
HCMV replication when knocked-down: DSC2 and FAC1. 
Again, the largest observed change in viral replication as determined by GFP 
intensity was observed with knock-down of ATP6VOC, which was the most 
highly enriched transcript in the infected RISC-IPs, and has been validated as 
being targeted solely by HCMV miR-US25-1 during infection. 
                                                        
4 The top 30 became 28, as there were no commercially available siRNAs for FALZ, and 
COMMD10 was confirmed as being a false positive in the first screen. 
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Figure 3.3 siRNA screen: TB40E GFP expression profile in fibroblast cells transfected with siRNAs against the top 30 
host-cellular targets of HCMV miRNAs (20 nM)(144hpi)(N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection were infected with TB40E. Virus replication was 
monitored via GFP plate reader. Negative control siRNA is represented as a solid black line and the 0.5 and 1.5 fold thresholds are 





The three genes that produced the biggest phenotypic effect on HCMV 
replication when knocked-down were chosen for further study: ATP6VOC, 
DSC2, and NUCB1. A de-convoluted pool of distinct pre-validated siRNAs was 
used to ensure that the observed viral phenotypes were not due to off target 
effects of the siRNA. While the vendors of these siRNAs validate the knockdown 
of target genes, and screen for common adverse phenotypes that might indicate 
off-target effects, these experiments will not have been performed within the 
context of infection. As such, extra caution is required in this type of study to 
validate the effect of siRNAs on viral replication. The results of the assessment 
of the de-convoluted pools of ATP6VOC, DSC2, and NUCB1 siRNAs are 
summarised in Figure 3.4. The ATP6VOC siRNAs, and to a lesser degree NUCB1 
siRNAs, produced a consistent decrease in TB40E replication. This gave 
confidence that the decreases observed in TB40E replication was not the result 
of an off target effect. The increase observed in TB40E replication with DSC2 
siRNA in the initial screen, was not recapitulated with the de-convoluted siRNA 
pool. This indicates that the result for DSC2 in the initial screen was likely due 
to an off-target effect of the siRNAs. 
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Figure 3.4 TB40E GFP expression profiles in fibroblast cells transfected 
with deconvoluted pool of ATP6VOC, DSC2, and NUCB1 siRNAs 
(20 nM)(120hpi)(N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection 
were infected with TB40E. Virus replication was monitored via GFP plate 
reader. Error bars represent the standard-deviation from the mean. 
 
Finally, the possibility that the observed defect in viral replication was a non-
specific consequence of a loss of cell-viability or IFNβ induction was ruled out. 
There was no change in cell viability or IFNβ induction in fibroblasts after 
ATP6VOC knock-down, when compared with the negative control 


















3.5. ATP6VOC expression is not required for entry and viral gene 
expression, but is critical for the formation of functional HCMV virions 
In order to further characterise the defect in viral replication after knock-down 
of ATP6VOC in fibroblast cells, it was necessary to dissect where in the HCMV 
viral lifecycle this defect occured. To this end, fibroblast cells were infected with 
TB40E after ATP6VOC knock-down, and defects in entry, penetration, and 
un-packaging were assayed using fluorescent microscopy and qRTPCR against 
viral genes during infection (Figure 3.5 and Figure 3.6). Defects in assembly and 
egress of the virus, were assayed using viral genome copy number analyses and 
plaque analyses (Figure 3.7). 
There was no apparent reduction in the proportion of GFP positive fibroblast 
cells after ATP6VOC knock-down when compared with the negative control 
siRNA transfected fibroblast cells, with 100% of cells GFP positive at 24 hpi 
(MOI=1) (Figure 3.5). 
Viral gene expression levels were calculated using the ΔΔct method, and 
normalised to the gene expression level in the 2 hpi negative control sample, to 
provide a relative measure of gene expression over time. Viral gene expression 
profiles were intact in fibroblast cells after ATP6VOC knock-down. Interestingly, 
between 24 and 72 hpi, there was a marginal (2 to 3 fold) increase in the 
expression of IE86 in fibroblast cells after ATP6VOC knock-down. However, at 
the majority of time-points viral gene expression was equivalent in fibroblast 
cells after ATP6VOC knock-down, when compared with negative control 
transfected fibroblast cells, for immediate early (IE86), late (UL83), and true 
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late (gH: UL75) genes (Figure 3.6). Taken together, these data demonstrate that 
ATP6VOC knock-down in fibroblast cells: does not prevent the entry of HCMV 
into fibroblast cells; does not prevent either intracellular trafficking of the 
virion or genome penetration; and does not affect viral gene expression, with 
viral mRNA transcribed as normal. 
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Figure 3.5 Fluorescence microscopy of fibroblast cells transfected with 
ATP6VOC siRNA and infected with TB40E (MOI=1) (24hpi) (10X 
magnification) 
Fibroblasts were transfected with ATP6OC siRNA, or a negative control siRNA. 
72 hours post transfection, cells were infected with TB40E at an MOI of 1, and 








Figure 3.6 Viral gene expression in fibroblast cells transfected with 
ATP6VOC siRNA and infected with AD169 (N=2) 
A. IE86 gene expression B. UL83 gene expression C. gH gene expression. 
Fibroblast cells were transfected with ATP6VOC siRNA or a negative control 
siRNA and at 72 hours post transfection were infected with AD169 at an MOI of 
1. Infected cells were harvested and genomic DNA isolated. Viral gene 
expression was calculated by the ΔΔct method, normalised to expression levels 
in the 2 hpi negative control sample. Error bars represent the standard-












































































Despite the apparent lack of effect on viral gene expression, there was a striking 
difference in the production of progeny virions in fibroblast cells after ATP6VOC 
knock-down compared with negative control siRNA transfected fibroblast cells 
(Figure 3.7). There was a decrease in the number of plaque forming units (PFU) 
of between 2 and 4 log10 (100 and 10000 fold) between 72 and 144 hpi in 
fibroblast cells after ATP6VOC knock-down compared with negative control 
transfected fibroblast cells, while a similar number of viral genomes were 
detected at each time point (Figure 3.7A and B, respectively). The relative 
'infectivity' of the progeny virus from these cells is given as a ratio in 









 2hpi 24hpi 48hpi 72hpi 96hpi 120hpi 144hpi 
ATP6VOC 
siRNA 
1:10 1:0.2 1:0.4 1:69 1:27 1:13 1:1.4 
Negative 
siRNA 
1:16 1:7.5 1:3540 1:6250 1:1610 1:480 1:107 
        
Figure 3.7 Relative viral genome copy number, PFU/mL, and genome 
copy number : PFU ratios from lysates of fibroblast cells transfected with 
ATP6VOC siRNA of negative control siRNA and infected with TB40E (N=3) 
(MOI=1) 
A. Genome copy number B. PFU/mL C. Genome copy number : PFU ratio 
Fibroblast cells were transfected with ATP6VOC siRNA or a negative control 
siRNA and at 72 hours post transfection were infected with AD169 at an MOI of 
1. Infected cells were harvested by scraping into media, and were fractioned. 
Genomic DNA was isolated, and analysed for genome copy number by qRTPCR 
using gH and UL83 primer probes. Lysates of infected cells were analysed by 
















































The data presented in this chapter identify the miR-US25-1 target ATP6VOC as a 
critical host factor that is required for HCMV replication in fibroblast cells in 
vitro. Marginal changes (<1.5 fold) in viral replication were observed for the 
majority of the validated and putative HCMV miRNA targets that were screened 
using siRNA knock-down (Figure 3.2). The biggest decreases in viral replication 
were observed in fibroblast cells transfected with siRNAs against ATP6VOC and 
NUCB1, and the biggest increases were observed in fibroblast cells transfected 
with DSC2 and FAC1. Of these, ATP6VOC knock-down was validated as being 
responsible for inhibiting viral replication using a de-convoluted pool of siRNAs.  
Further examination confirmed a post-entry defect, as both GFP expression and 
viral gene expression profiles were similar in fibroblast cells after ATP6VOC 
knock-down when compared with negative control transfected fibroblast cells. 
However, there was a striking difference in the progeny virus produced by cells 
transfected with ATP6VOC siRNA: despite similar numbers of viral genomes 
being produced in fibroblast cells after ATP6VOC knock-down when compared 
with negative control transfected fibroblast cells, there was a 2-4 fold decrease 
in the number of plaque forming units produced. 
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3.7. siRNA screening to identify novel host-virus interactions 
Several other groups have used similar approaches, either screening the entire 
host genome, select pathways, or druggable targets, in order to identify critical 
host-factors for several alphaviruses, influenza A virus, HCV, HIV and HPV [229-
240]. The real power and novelty in the screen presented here is that rather 
than blindly screening for host-cell factors that are involved in virus replication, 
this screen focused on genes that appear to be actively regulated during 
infection by HCMV miRNAs. While this approach proved fruitful in this instance, 
there are  several changes in experimental design that might have improved the 
sensitivity of the screen in identifying critical factors. 
One consideration to be made is that the artificial conditions experienced by 
infected cells in vitro may obscure important host factors. It is possible that 
certain pathways regulated by HCMV miRNAs may only be relevant under 
certain biological conditions and that the serum and nutrient rich cell-culture 
environment may obscure these interactions. BCKDHA and CCNE1/2 may 
represent examples of this. BCKDHA function is only likely to be relevant in an 
environment where BCAAs are depleted. CCNE1/2 inhibition may only be 
applicable in conditions of cell stress where the cell cycle is arrested. In these 
cases it would be informative to test the effect of BCKDHA knock-down in BCAA 
starved conditions, and CCNE1/2 in serum starved conditions. As discussed in 
Chapter 1 and 2, there is also a likelihood that miRNA function may well be cell 
specific, as is evident for other HCMV gene products. As such, it would be 
informative to repeat this screen in endothelial and epithelial cells. 
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Within the context of miRNA regulation of host-cellular genes, the use of an 
siRNA screen is perhaps not as representative as a screen that would allow for 
the overexpression of these factors. However, within the scope of this study, this 
would not have been practical. Recently, other groups have developed 
lenti-viral libraries that allow the overexpression of factors to analyse their 
relevance within the context of infection. This has been particularly informative 
for analysing the effect of interferon-stimulated genes on innate immune 
responses to several viruses [241, 242]. Using this type of screen allied with 
siRNAs for putative miRNA targets would be a powerful technique for 
identifying critical roles of the regulation of specific miRNA targets during 
infection. 
A major problem with interpretation of siRNA screen data is highlighted in the 
variable results obtained from the de-convoluted pool of siRNAs against DSC2. 
Commercial siRNAs are pre-validated and screened for common biomarkers of 
off-target effects. However, they are not screened for off-target effects within 
the context of infection and phenotypically innocuous off-target effects in 
uninfected cells can have a dramatic effect on infection. As such, one 
improvement would be to use de-convoluted siRNA pools for every gene within 
the screen to avoid false positives. However the increased cost of such an 
approach would have proved prohibitive within the scope of this study. 
Finally, the inherent redundancy of eukaryotic processes represents an obstacle 
when using an siRNA screen to identify novel host-virus interactions. As 
highlighted earlier, there is evidence that viral miRNAs have the capacity to 
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target multiple genes within related pathways and it seems likely that these 
interactions may have evolved to circumvent the redundancy that is prevalent 
in eukaryotic processes, in order to bring about a change in host-cell phenotype 
during infection. The importance of targets within these pathways to HCMV 
biology may therefore not be apparent unless several genes within these 
pathways are knocked-down. Attempts were made to circumvent this, with the 
co-transfection of siRNAs against cyclin and nucleobindin family members 
within the initial siRNA screen. However, until there is a more thorough 
working knowledge of the host-cellular targets of HCMV miRNAs, this problem 
will be difficult to overcome. 
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4. v-ATPase acidification of host-cellular compartments 
is required for the formation of the HCMV virion 
assembly compartment 
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4.1. Differentiating the roles of ATP6VOC and miR-US25-1 in infection 
The data presented in the previous chapters demonstrate that ATP6VOC is a 
target of HCMV miR-US25-1 during infection, that ATP6VOC expression is 
critical for virus replication, and that it likely has functions in the assembly and 
egress of HCMV during infection. 
However, the role of miR-US25-1 regulation of ATP6VOC during infection is 
unclear. It seems unlikely that HCMV would encode an miRNA to regulate a 
host-cellular transcript during infection in order to disrupt HCMV production. 
As such, it seems likely that the viral phenotype identified in the siRNA screen is 
not reflective of the role of miR-US25-1 during infection, as it is the result of a 
complete knock-down of ATP6VOC at early time-points, which is unlikely to 
occur via miRNA mediated regulation of ATP6VOC within the context of 
infection. 
Nevertheless, the loss of function experiments presented in Chapter 3 have 
revealed ATP6VOC as being a critical host factor in HCMV infection and this has 
intriguing implications for the roles of the endocytic and secretory pathways in 
HCMV assembly and egress. These roles are explored further in this chapter. 
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4.2. The HCMV viral assembly compartment 
Herpesvirus assembly is a complex process (as reviewed in [8, 243]). In brief, 
viral DNA is synthesised in the nucleus and packaged into nucleocapsids. These 
particles then escape the nuclear lamina and bud through the inner nuclear 
membrane into the perinuclear space, acquiring a primary envelope in the 
process. This envelope then fuses with the outer nuclear membrane allowing for 
egress of the nucleocapsid into the cytoplasm [8].  
Once in the cytoplasm, tegument proteins assemble on the capsid, and 
secondary envelopment occurs as the virion buds into trans-golgi network 
(TGN) or endoplasmic reticulum (ER) derived plasma membranes that contain 
viral glycoproteins. The mature virion is then trafficked to the cell surface 
where it egresses into the extracellular space [8].  
During HCMV infection, there are a number of dramatic changes that occur in 
the cell to facilitate viral assembly. The lytic replication cycle is long, with an 
initial phase of 96 hours where very few viral progeny are produced. During this 
time, the cytoskeleton remodels [244], nuclei increase in volume and change in 
morphology [72], and secretory and endocytic vacuoles reorganise [244, 245].  
The most striking result of these changes is the aggregation of elements of the 
endocytic pathway and secretory apparatus to form a juxtanuclear cytoplasmic 
inclusion. This inclusion is the HCMV virion assembly compartment (VAC).  
The VAC was first described with the use of immunofluorescence microscopy as 
a region of infected cells where several cytoplasmic virion proteins (pp150, gB, 
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gH, pp28 and gp65) colocalise late in infection. These proteins also overlap with 
markers of trans-golgi compartments of the host-cellular secretory apparatus 
(GM130, Mann II) and this structure lies at the centre of a relocated microtubule 
organising centre [72, 74]. Since these initial observations, several other 
host-cellular and viral components have been shown to localise to the site of 
viral assembly [72, 75-77, 188, 246, 247]. In addition to markers of 
compartments derived from the trans-golgi network, (TGN46, p230, GM130, 
and Mann II), compartments derived from the early endosomal (EEA1), late 
endocytic (VPS4), and ESCRT-III (CHMP1A) pathways colocalise with viral 
markers within the VAC. While these markers all relocalise to this juxtanuclear 
inclusion, they each appear to have distinct localisations from one another, 
leading some to suggest that each compartment may have distinct biological 
roles in viral assembly [247]. Altogether, the evidence suggests that these 
host-cellular cytoplasmic compartments are re-organised in a deliberate fashion 
during HCMV infection to facilitate the recruitment of viral tegument proteins to 
the nucleocapsid before the mature virus buds into an exocytic vesicle where 
the virion acquires a final envelope, which contains the requisite quota of viral 
glycoproteins [80]. 
Despite evidence of the constituents of the VAC, the host-cellular and viral genes 
that play roles in the biogenesis of the VAC are poorly understood. 
Das et al  described three HCMV tegument proteins that have been identified as 
important contributors to VAC biogenesis; UL48, UL94, and UL103 [75]. From 
previous studies of these proteins and their orthologues in other Herpesviridae 
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family members, UL48 is thought to be a ubiquitin specific protease with roles 
in capsid transport, UL94 a single stranded DNA binding protein involved in 
cytoplasmic egress, and UL103 a factor important for late stage replication and 
egress. Knock-down of these proteins and subsequent infection with HCMV 
results in a complete loss of progeny virus (for UL94 and UL103 knock-down) 
or an increase in the number of defective particles and a 2 log10decrease in 
infectious virus (for UL48 knock-down) [75].  
Bughio et al [188] described 4 proteins encoded by the UL133-138 locus as 
being critical for VAC biogenesis in endothelial cells, with a UL133-138NULL 
strain of TB40E exhibiting defective replication kinetics. Interestingly, this locus 
is disposable in fibroblast cells. Conversely, Schauflinger et al [79] 
demonstrated that UL71, a viral protein required in fibroblast cells for assembly 
compartment formation and efficient secondary envelopment, is dispensable in 
endothelial cells. These examples highlight that the determinants of VAC 
biogenesis appear to be tropism specific. 
In addition to these viral factors, several host factors have been identified 
whose regulation during infection is essential in VAC biogenesis. Particularly 
relevant to this study, several of these have been shown to be regulated by 
HCMV encoded miRNAs. 
Hook et al demonstrated that VAMP3, RAB5C, RAB11A, SNAP23, and CDC42 are 
the targets of HCMV encoded microRNAs. Down regulation of these endocytic 
and secretory pathway genes by miR-UL112-1, US5-1, and US5-2, appear to 
facilitate the formation of the VAC [172]. It is particularly interesting that the 
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down-regulation of these genes also reduces the levels of secreted 
pro-inflammatory cytokines TNFα and IL-6. This highlights that the subjugation 
of the endocytic and secretory pathways to facilitate VAC biogenesis may also 
be responsible for reducing the inflammatory response to infected cells in vivo, 
dampening the host immune response to infected cells at late times post 
infection. 
Although VAC formation has not been shown to be explicitly required for 
functional virion formation, there is an overriding theme that the disruption of 
factors involved in VAC biogenesis results in a defective viral phenotype. This 
lends to a hypothesis that VAC formation is required for the efficient assembly 
of HCMV. 
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4.3. v-ATPases in the endocytic and secretory pathways 
The v-ATPase is a membrane spanning, multi-domain ion pump that is 
responsible for the regulation of pH in membrane-bound organelles throughout 
the cell. These channels consist of a luminal V1 domain, which is responsible for 
the hydrolysis of ATP, and a trans-membrane VO domain which forms the proton 
channel. ATP6VOC is a critical component within the VO domain [248]. 
The v-ATPase is crucial in the establishment of a low intraluminal pH in 
vacuoles, and this is pivotal for a variety of processes within the endocytic and 
secretory pathways. The endocytic pathway is the means by which cells process 
extracellular cargo. Extracellular macromolecules are transported across the 
outer cell membrane by receptor/clathrin mediated endocytosis, 
macropinocytosis, or in caveolae. Once internalised, these macromolecules are 
sorted in a series of intermediate compartments, and either recycled to the cell 
surface, or degraded within the lysosome. An acidic intraluminal pH in 
endosomes facilitates the dissociation of internalised ligand-receptor 
complexes, which allows cells to selectively internalise extracellular 
macromolecules and recycle their associated receptors back to the cell 
membrane [249, 250]. The intracellular sorting of these macromolecules is also 
dependent on the acidification of vacuoles. Trafficking between early and late 
endosomes via endosomal carrier vesicles, traffic between endosomes and 
lysosomes, and the fusion of multivesicular bodies with lysosomes are all 
dependent on the activity of the v-ATPase [251, 252]. Finally, at the terminus of 
the endocytic pathway, the degradative enzymes within the lysosome require 
 133 
an acidic pH in order to function, which is again dependent of the v-ATPase 
[249, 253]. 
The secretory pathway is the means by which newly synthesised proteins are 
sorted and trafficked to their final destination within the cell. The intraluminal 
pH of secretory compartments plays a crucial role in this process. Many newly 
synthesised proteins are translated by ribosomes that are tethered on the ER 
surface, and these peptides co-translationally enter the ER lumen [254]. These 
proteins are then sorted via cis-, medial-, and trans-golgi compartments for 
constitutive or regulated secretion, or for lysosomal degradation. The v-ATPase 
acidifies these compartments, facilitating the post-translational modification of 
newly synthesised proteins within trans-golgi vacuoles and for the proper 
targeting of these proteins to their termini [254-256].  
Within the context of infection the possible roles of ATP6VOC and the endocytic 
and secretory pathways are intriguing. The majority of viruses exploit the 
endocytic pathway to obtain entry into cells, typically by receptor mediated 
endocytosis in clathrin coated vesicles. Once internalised, several viruses 
exploit the acidification of these endosomes to facilitate release of the viral 
genome into the host cell. One elegant and well-studied example is influenza A 
virus. Haemaglutinin (HA) molecules on the surface of influenza A virions bind 
sialic acid receptors on the cell surface which facilitate the internalisation of the 
virion into the cell. The acidification of virus containing endosomes causes a 
conformational change in the HA molecules that allow for fusion between the 
influenza lipid membrane and the endosome membrane, which causes release 
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of the viral RNPs into the cytoplasm [257, 258]. For some other viruses, such as 
Ebola virus and SARS coronavirus, acid dependent cleavage of viral 
glycoproteins by endosomal proteases is required for the penetration of the 
viral genomes in the cytosol [259, 260]. The roles of acidification in these 
processes is summarised in Figure 4.1. 
 
Figure 4.1 Summary of roles of acidification in membrane trafficking 
processes.  
Adapted from Forgac, Nature Reviews Molecular Cell Biology, 2007. 
In addition to the role of the v-ATPase in vacuolar acidification, there have also 
been several observations in a variety of contexts that the Vo domain of the 
v-ATPase may have an intrinsic membrane fusion activity. In mice, C. elegans, 
and Drosophila, the Vo domain has been shown to interact with VAMP-2, 
syntaxin-1 and Ca2+ release channels to directly catalyse the mixing of two lipid 
bilayers, in an acidification dependent manner [261-265]. 
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Within the context of HCMV infection, the role of ATP6VOC is potentially more 
complicated due to the distinct methods of entry into different host cell types. In 
epithelial and endothelial cells, entry predominantly occurs by endocytosis, and 
penetration by low pH fusion[44]. In fibroblast cells, however, entry 
predominantly occurs by plasma membrane fusion which allows the naked 
nucleocapsid to penetrate the cytosol directly [48]. As this process is pH 
independent, one would predict that v-ATPase activity should not effect HCMV 
entry into fibroblast cells, and this is supported by the observations presented 
in Chapter 3. Conversely, v-ATPase activity is likely to be required for entry and 
penetration of endothelial and epithelial cells. 
Post-entry, the endocytic and secretory pathways are subjugated during HCMV 
infection to facilitate VAC biogenesis. It is possible that an acidic pH within these 
compartments is required for viral assembly. With the v-ATPase responsible for 
the acidification of these compartments, it is plausible that the defect that was 
identified in HCMV replication in fibroblast cells after ATP6VOC knock-down 
could be the result of a critical defect in VAC biogenesis, or that acidification 
within the VAC is critical for virion assembly. 
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4.4. Hypothesis and aims 
It was hypothesised that ATP6VOC might be required for the formation of the 
HCMV virion assembly compartment, and this may be critical for the assembly 
of functional virions. 
The aims of the work presented in this chapter were to: 
1. Interrogate HCMV VAC biogenesis in fibroblast cells after knock-down of 
ATP6VOC. 
2. De-convolute the membrane fusogenic and vacuolar acidification effects 
of ATPVOC within the context of HCMV infection. 
3. Characterise and identify defective phenotypes of progeny virus from 
fibroblast cells lacking the expression of ATP6VOC. 
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4.5. ATP6VOC is required for HCMV virion assembly compartment 
biogenesis 
Immunofluorescence microscopy was performed to observe the distribution of 
both host-cellular (TGN46 and EEA1) and viral (pp28) markers of the HCMV 
VAC in fibroblast cells transfected with an siRNA against ATP6VOC or a negative 
control siRNA. In cells transfected with a negative control siRNA, host-cellular 
proteins TGN46 and EEA1 colocalised with the viral tegument protein pp28 in a 
region adjacent to an enlarged, kidney shape nucleus (Figure 4.2). This staining 
was primarily diffuse, lacking defined boundaries, and was consistent in 
localisation and appearance with previous reports of the HCMV VAC [74-76, 
188, 246, 247].  
In fibroblast cells transfected with ATP6VOC siRNA, there were several 
observable morphogenic differences when compared with negative control 
siRNA transfected fibroblasts. The cells were noticeably smaller under low 
magnification (as can be seen in Figure 3.5), and using high magnification 
confocal microscopy there was a clear decrease in nuclear volume, and the 
characteristic kidney shape observed after infection in negative control siRNA 
transfected fibroblasts was not as apparent. While the host-cellular markers of 
the VAC appeared to redistribute to a similar juxtanuclear location within the 
cell, the staining of TGN46 was less diffuse than the pattern observed in 
negative control siRNA transfected fibroblast cells, and the staining of EEA1 had 
clear boundaries, indicative of large vesicular compartments. Most strikingly, 
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pp28 did not colocalise with the host-cellular markers of the VAC (Figure 4.2). 
Images from a wider field of view are shown in Figure 4.3A.  
Importantly, these qualitative observations were quantifiable. Scatter plots of 
pixel intensity from a multi-cell field demonstrated that staining for TGN46 and 
pp28 overlapped extensively in negative control siRNA transfected fibroblast 
cells, but did not overlap in fibroblast cells after ATP6VOC knock-down (Figure 
4.3B). Colocalisation analyses of TGN46, EEA1 and pp28 were performed and 
Pearson's R scores calculated (1=convergent 0=divergent) from several multi-
cell images. The frequency of TGN46 and pp28 staining convergence was high in 
negative control siRNA transfected fibroblast cells (R=0.58), and low in 
ATP6VOC siRNA transfected fibroblast cells (R=0.16). Similarly, EEA1 and pp28 
staining convergence was high in negative control fibroblast cells (R=0.41) and 






Figure 4.2 Immunofluorescence microscopy 
of the HCMV viral assembly compartment in 
fibroblast cells transfected with ATP6VOC 
siRNA or negative control siRNA (144 hpi) 
(63X magnification, 2x zoom) 
Fibroblast cells were transfected with ATP6VOC 
siRNA or negative control siRNA and at 72 hours 
post transfection were infected with AD169. At 
144 hpi cells were fixed, permeabilised, and 
stained for early endosomes or trans golgi 
vacuoles (EEA1:green or TGN46:green), viral 
tegument protein (pp28:red), and nuclei 
(DAPI:blue). Images were acquired on a Zeiss 
LSM710 confocal microscope. Images presented 
here are maximum intensity projections compiled 
from multiple 0.33 μm slices through the Z-axis. 3D 
renders of these images are provided in 
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Figure 4.3 Immunofluorescence 
microscopy of the HCMV viral assembly 
compartment in fibroblast cells 
transfected with ATP6VOC siRNA 
(144 hpi) (63X magnification) 
A. Fibroblast cells were transfected with 
ATP6VOC siRNA or negative control 
siRNA and at 72 hours post transfection 
were infected with AD169. At 144 hpi 
cells were fixed, permeabilised, and 
stained for early endosomes or trans golgi 
vacuoles , (EEA1:green or TGN46:green), 
viral tegument protein (pp28:red) and 
nuclei (DAPI:blue). Images represent 
single slices through the Z-axis. B. 
Representative scatter-plot showing 
average pixel signal intensity in red 
(pp28) and green (EEA1) channels from 
multicell images (n=16 for ATP6VOC and 
n=9 for negative siRNA). Individual 
images in the Z-field were analysed using 
Fiji image analysis software. C. Pearson's 
R-value for colocalisation of TGN46 or 
EEA1 and pp28 in ATP6VOC or negative 




There was a possibility that this defect was due to the gross disruption of 
secretory and endocytic pathways as a consequence of ATP6VOC knock-down. 
To assess whether this was the case, the distribution of these markers in 
unifected cells was analysed by immunofluorescence microscopy (Figure 4.4A) 
and the abundance of these proteins was analysed by western blot in uninfected 
cells and infected cells (Figure 4.4B and C). The distribution of both TGN46 and 
EEA1 was similar in fibroblast cells after ATP6VOC knock-down when 
compared with fibroblasts transfected with a negative control siRNA . The 
abundance of TGN46 and EEA1 proteins were also equivalent in both ATP6VOC 
siRNA and negative control siRNA transfected fibroblast cells, in uninfected cells 
and also at 144 hours post infection (Figure 4.4B and C). 
Taken together, the data presented in Figure 4.2, Figure 4.3, and Figure 4.4 
demonstrate that ATP6VOC is required for the re-localisation of host-cellular 
compartments during HCMV VAC biogenesis.
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Figure 4.4 Immunofluorescence microscopy of trans-golgi network and early endosomes in fibroblast cells transfected 
with ATP6VOC siRNA or a negative control siRNA (63 x magnification, 2 x zoom) (72 hours post transfection/hpi) 
A. Fibroblast cells were transfected with ATP6VOC siRNA or negative control siRNA. At 72 hours post transfection cells were fixed, 
permeabilised, and stained for early endosomes or trans golgi vacuoles. Images are maximum intensity projections compiled from 
multiple 0.33 μM slices through the Z-axis. B. Western blot analyses of ATP6VOC siRNA and negative control and transfected 
fibroblast cells against markers of trans-golgi vacuoles (TGN46), early endosomes (EEA1). Infected cells were harvested at 72 hpi. 
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4.6. v-ATPase acidification activity is required in fibroblast cells for 
efficient virus production and VAC formation in fibroblast cells 
There are two different roles ascribed to ATP6VOC: as a critical component of 
the v-ATPase responsible for acidifying vacuoles; and as a component of the VO 
domain which has acidification independent roles in the fusion of plasma 
membranes [261-265]. As such, it was important to establish which of these 
processes was responsible for the defective VAC phenotype that was observed 
as a consequence of ATP6VOC knock-down.  
To ascertain whether inhibiting acidification of endosomal vacuoles resulted in 
a similar reduction in viral replication, viral growth assays were performed 
using the TB40E and chemicals that block acidification of vacuoles; chloroquine 
and bafilomycin. Chloroquine indirectly blocks the acidification of vacuoles. It 
freely diffuses through cells, but upon reaching an acidic compartment it 
undergoes a change of conformation that renders it impermeable, causing it to 
accumulate in these compartments[266]. This acts to buffer any further pH 
decrease in these vacuoles, inhibiting their functionality. Bafilomycin is a 
specific inhibitor of acidification, and directly binds ATP6VOC to inhibit the 
proton channel within the v-ATPase [267]. Fibroblast cells were incubated in 
media containing chloroquine during infection. Inhibition of acidification of 
vacuoles within the cell with chloroquine had a dose dependent inhibitory effect 
on the replication of TB40E as monitored by GFP intensity. At the highest dose 
of 25 μM the inhibition of TB40E GFP intensity was of a similar magnitude to 
that observed in cells transfected with ATP6VOC siRNA (Figure 4.5A). Again, the 
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observed inhibition of replication was more apparent by plaque analysis of 
lysates from treated cells 120 hpi, where a >2 log10 decrease in PFU was 





Figure 4.5 TB40E GFP expression profiles and plaque analysis in 
fibroblast cells treated with chloroquine (N=3) 
A. TB40E GFP intensity up to 144 hpi in fibroblast cells treated with 1.25-25 μM 
chloroquine. B. Virus produced from lysates of cells treated with 1.25-25 μM 
chloroquine at 120hpi. Fibroblast cells were infected and 2 hours later fresh 
media containing 1.25-25 μM Chloroquine was overlaid. Viral replication and 





































Treatment with bafilomycin was more complicated due to the cytotoxicity 
associated with prolonged exposure. As a result, treatment over a 7 day 
infectious time-course was not possible. In order to minimise exposure of the 
cells to the toxic effects of prolonged exposure to bafilomycin, while maximising 
the effect of inhibiting v-ATPase activity, fibroblast cells were treated with 
0.1 μM bafilomycin at either 72 hpi or 96 hpi. These time-points were selected 
to have a maximum effect on HCMV VAC biogenesis. Treatment with 
bafilomycin had a dramatic effect on halting further TB40E replication 
(Figure 4.6A). Inhibition of v-ATPase induced acidification using bafilomycin 
had profound effects on the infectivity of progeny virus from treated cells, with 
a 2 log10 decrease in PFU/mL in cells treated at 96 hpi, and a 4 log10decrease in 
PFU/mL in cells treated from 72hpi. However, despite there being no visible 
increase in cytopathic effect, it could not be ruled out that these observations 







Figure 4.6 TB40E GFP expression profiles and plaque assay in fibroblast 
cells treated with 0.1 μM bafilomycin at 72 and 96 hpi (N=3) 
A. GFP intensity in TB40E infected fibroblast cells treated at 72 or 96 hpi with 
0.1 μM bafilomycin. B. Plaque assay at 120hpi from cells treated at 72 or 96hpi 
with 0.1 μM bafilomycin. Note: standard deviation is plotted but was minimal 
between replicates and is not visible on a log10 scale. For GFP expression 
profiles, fibroblast cells were infected with TB40E and were overlaid with fresh 
media containing 0.1 μM bafilomycin at 72 hpi or 96 hpi, and virus replication 
was monitored by GFP plate reader. For plaque assays, fibroblast cells were 
treated with 0.1 μM bafilomycin at 72 or 96 hpi. At 120 hpi, infected cells were 


































To ascertain whether the defective phenotype observed in Figure 4.2 and Figure 
4.3 could be recapitulated when vATPase activity was blocked by another 
mechanism, siRNAs against other components of the vATPase were used 
(ATP6V1H and ATP6V1A). ATP6V1H is critical for ATP hydrolysis and vATPase 
function is dependent upon this activity [268], and although the function of 
ATP6V1A has not been elucidated, like other components of the v-ATPase it is 
likely to perform a similarly crucial role . Critically, both of these components lie 
in the V1 domain, so the membrane fusion functions of VO were not inhibited by 
their knock-down. TB40E replication was inhibited in fibroblasts after 
ATP6V1A and ATP61H knock-down when compared with fibroblast cells 
transfected with negative control siRNA, and the magnitude of this inhibition 
was almost identical to that observed after ATP6VOC knock-down (Figure 4.7). 
 
Figure 4.7 TB40E GFP expression profiles in fibroblasts after ATP6VOC, 
ATP6V1A, or ATP6V1H knock-down 
Fibroblasts were transfected with 20 nM AT6VOC, V1H, V1A or a negative 
control siRNA. 72 hours post transfection cell were infected with TB4OE, and 





















This inhibition was analysed by immunofluorescence microscopy in fibroblast 
cells after ATP6V1H knock-down (Figure 4.8). TGN46 and EEA1 failed to 
colocalise with pp28 after ATP6V1H knock-down, and the distribution of these 
markers was very similar to the phenotype observed when ATP6VOC was 
knocked down (Figure 4.8A). Again, these observations were corroborated by 
quantifying the colocalisation of these markers and Pearson's R scores were 
calculated (following knock-down of ATP6V1H, TGN46/pp28=0.23 and 
EEA1/pp28=0.28) (Figure 4.8B). 
Taken together, the data presented in Figure 4.5, Figure 4.6, Figure 4.7 , and 
Figure 4.8 demonstrate that the role of ATP6VOC in VAC formation is dependent 
upon its function within the v-ATPase in acidifying vacuoles, rather than any 


































































Figure 4.8 Immunofluorescence 
microscopy of the HCMV viral assembly 
compartment in fibroblast cells 
transfected with ATP6V1H siRNA (63 x 
magnification) (144 hpi) 
A. Immunofluorescence microscopy in 
AD169 infected fibroblast cells transfected 
with ATP6V1H siRNA and stained for early 
endosomes (EEA1:green), viral tegument 
protein (pp28:red) and nuclei (DAPI:blue). 
Images represent single slices through the 
Z-axis. B. Pearson's R-value for 
colocalisation of TGN46 or EEA1 and pp28 
in ATP6V1H or negative control siRNA 
transfected fibroblast cells (n=20). 
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4.7. Characterising progeny virus from fibroblast cells following 
ATP6VOC knock-down 
The data shown in Chapters 4.5 and 4.6 demonstrate that the v-ATPase is 
required for formation of the HCMV VAC, and this coincides with either 
defective assembly or egress of the virus (Chapter 3.5). However, the exact 
nature of the viral defect that occurs as a result of v-ATPase inhibition was 
unclear. There were several scenarios that could explain these observations:  
 Viral assembly was normal, and there was a failure of viral egress; 
 Viral assembly was grossly defective, and viral egress was occurring; 
 A key stage of viral assembly was specifically defective, and viral egress 
was occurring; 
 Both viral assembly and egress were grossly defective. 
In order to establish which of these scenarios was the cause of the assembly 
defect, intracellular and supernatant virus from fibroblast cells after ATP6VOC 
knock-down, or negative control siRNA transfected fibroblast cells were 
isolated and analysed for genome copy number, PFU/mL, and viral protein 
abundance. 
4.7.1. Viral genome copy number and PFU/mL differ in supernatant and 
cell associated virus after ATP6VOC knockdown compared to the negative 
control siRNA transfected fibroblast cells 
The genome copy number in cell associated virus fractions were strikingly 
similar after ATP6VOC knock-down in fibroblast cells compared with negative 
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control siRNA transfected fibroblast cells, with minor differences which were 
within the margin of error (1.2 fold change) (Figure 4.9A and B). In the 
supernatant virus fraction, there was a decrease in genome copy number of 
3.4 fold when in fibroblast cells after with ATP6VOC knock-down compared 
with the negative control transfected fibroblast cells. 
The titres of cell associated virus from fibroblast cells after ATP6VOC 
knock-down were nearly 2 log10 lower than the titres from negative control 
siRNA transfected fibroblast cells. The titres of supernatant purified virus from 
fibroblast cells after ATP6VOC knock-down were nearly 3 log10 lower than the 
titres from negative control siRNA transfected fibroblast cells (Figure 4.9C and 
D). These data are consistent with previous results from plaque assay on cell 
associated and supernatant virus combined, which showed a 2-3 log10 decrease 
in viral titres (Figure 3.7). However, the data shown in Figure 4.9 demonstrate 
that there is an order of magnitude difference in the decrease in titres when 
comparing cell-associated with supernatant purified virus from cells transfected 
with ATP6VOC siRNA. This is particularly apparent when these data are 
displayed on a linear scale as a fold change (Negative control siRNA÷ATP6VOC 
siRNA). There was a 77.3 fold reduction in cell associated and a 727.3 fold 
reduction in virus titres in supernatant purified virus in fibroblast cells after 
ATP6VOC knock-down compared with negative control siRNA transfected 
fibroblast cells (Figure 4.9D).  
The observation that a dramatic decrease in the infectivity of progeny virus 
from in fibroblast cells after ATP6VOC knock-down can not be accounted for by 
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a decrease in genome copy number alone is suggestive of a defect in viral 
assembly and egress. 
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Figure 4.9 Virus infectivity and genome copy number in cell associated and purified supernatant virus from AD169 
infected fibroblast cells transfected with ATP6VOC siRNA or negative control siRNA (N=2) (144 hpi 
A. Relative genome copy number (relative to negative)B. Fold change in genome copy number C.  PFU/mL D. Fold change in 
PFU/ml. Fibroblasts were transfected with ATP6VOC siRNA, or negative control siRNA and at 72 hours post transfection cells were 
infected with AD169 at an MOI of 1. At 168 hpi, supernatant virus was purified and infected cells harvested. Supernatant and cell 









































































































































4.7.2. Viral protein levels in fibroblast cells after ATP6VOC knock-down 
are equivalent in intracellular virus fractions, but dramatically decreased 
in supernatant virus fractions, compared with negative control 
transfected fibroblast cells  
Western blot analysis was performed to ascertain the abundance of viral 
proteins in supernatant and cell associated virus from fibroblast cells after 
ATP6VOC knock-down compared with negative control siRNA transfected 
fibroblast cells. Immediate early proteins IE72 and IE86, glycoprotein gB, and 
tegument protein pp28 were assayed. Consistent with the genome copy number 
analyses (Figure 4.9) and gene expression analyses (Figure 3.6), the levels of 
protein in the cell associated virus were equivalent, with the exception of IE72 
which appeared to be more abundant in fibroblast cells after ATP6VOC 
knock-down (1.5 fold higher)(Figure 4.10). In the supernatant purified virus, 
the abundance of viral proteins in fibroblast cells after ATP6VOC knock-down 
were dramatically decreased compared with supernatant virus from negative 
control siRNA transfected fibroblast cells. pp28 and gB protein abundance were 
16 fold and 12 fold lower, respectively, in supernatant virus from fibroblast cells 
after ATP6VOC knock-down, with supernatant virus from negative control 
siRNA transfected fibroblast cells. It should be noted that IE86 and IE72 
proteins are not packaged into the progeny virions, and as such were not 






Figure 4.10 Western blot analysis of viral proteins in supernatant and 
cell associated AD169 in from fibroblast cells transfected with ATP6VOC 
siRNA or a negative control siRNA (N=1) 
A. Fibroblasts were transfected with ATP6VOC siRNA, or negative control siRNA 
and at 72 hours post transfection cells were infected with AD169 at an MOI of 1. 
At 168 hpi, supernatant virus was purified and infected cells harvested. Virus 
samples were lysed in laemmli buffer and western blot analyses were 
performed using specific primary antibodies, and LiCOR secondary antibodies. 
B. Quantification of western blot data, normalised first to b-Actin and then to 









































































































































The data presented in Figure 4.10 show an increase in the abundance of IE72 in 
infected cells transfected with ATP6VOC siRNA (at 144 hpi). To explore this 
phenomenon and the impact, if any, on the HCMV gene expression temporal 
cascade in more detail, western blot analysis was performed on infected cell 
lysates against IE72, IE86, gB, and pp28 over a time-course (Figure 4.11). These 
data demonstrate that there is a greater abundance of IE72 and IE86 protein at 
48, 72, and 96 hours post infection in fibroblast cells after ATP6VOC 
knock-down compared with negative control siRNA transfected fibroblasts. 
These increases in IE protein abundance were accompanied by increases in the 
abundance of gB protein (a late protein product) and pp28 (a true late protein 
product) from 48 and 72 hours post infection, respectively. When these data 
were quantified, it indicated that the order of magnitude of the increases in 
protein abundance in fibroblast cells after ATP6VOC knock-down was between 
2 and 3 fold at early time-points for all genes tested at the same MOI (Figure 
4.12).  
The protein abundance data in Figure 4.11 and Figure 4.12 allied with the viral 
gene expression data in Figure 3.6 indicate that the viral gene expression 
cascade appears to be initiated more robustly in fibroblast cells after ATP6VOC 
knock-down, and this appears to translate to a more robust induction of other 
genes later in the cascade. Logic would suggest that the cause of this 
phenomenon is likely to be independent of the observations that VAC formation 
and viral assembly are defective in these cells as: a). it is counter intuitive that 
an induction in viral gene expression would lead to a defect that results in less 
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infectious virus, and b). these differences in protein expression occur at a time-
point before assembly compartment biogenesis occurs. This suggests that the 
knockdown of ATP6VOC and subsequent inhibition of v-ATPase activity or VO 
induced membrane fusion has other effects early in infection that result in a 
more robust initiation of the viral gene expression cascade. 
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Figure 4.11 Licor western blot analysis of viral proteins in AD169 infected fibroblast cells transfected with ATP6VOC or 
negative control siRNA (24-168 hpi) 
Fibroblasts were transfected with ATP6VOC siRNA, or negative control siRNA and at 72 hours post transfection cells were infected 
with AD169 at an MOI of 1. At 24 hour time-points, infected cells were harvested in laemmli buffer. Western blot analyses were 
performed using specific primary antibodies, and LiCOR secondary antibodies. 
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Figure 4.12 Viral protein expression profiles in AD169 infected fibroblast cells transfected with ATP6VOC siRNA or a 
negative control  
A. IE72; B. IE86; C. gB; D. pp28. Relative gene expression normalised to β-Actin. Quantification of western blots shown in Figure 














































































































































In Chapter 3, ATP6VOC was identified as a critical host factor required for 
HCMV replication. The data in this chapter demonstrate that ATP6VOC activity 
is required for the proper formation of HCMV VAC, likely as part of the v-ATPase 
which is responsible for acidification of host-cellular membrane bound 
compartments. Furthermore, the evidence presented here in combination with 
that in the literature suggests that the biogenesis of the VAC is required for the 
efficient production of functional virions [79, 172, 188]. Although it was not 
directly confirmed, this is likely due to a defect in the acidification of these 
compartments after ATP6VOC knock-down, as knock-down of another critical 
component of the vATPase (ATP6V1H) and specific chemical inhibitors of 
vacuole acidification (chloroquine and bafilomycin) recapitulated these defects 
in VAC biogenesis and viral replication (Figure 4.8) [79, 172, 188]. However, it 
was not entirely ruled out that the intrinsic membrane fusion function of 
ATP6VOC within the VO domain may also play a role [261-265]. 
Interestingly, and somewhat counter intuitively, ATP6VOC knockdown was 
associated with an earlier induction in immediate early protein expression 
which resulted in a more robust induction of late and true-late protein synthesis 
(Figure 4.11 and Figure 4.12).  
The dysfunction in the formation of the VAC was associated with drastic effects 
on progeny virions. While there was no decrease in intracellular viral genome 
copy number or protein abundance in intracellular virus, there was a robust 
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decrease in both the abundance of viral proteins and the genome copy number 
in extracellular virus after in fibroblast cells after ATP6VOC knock-down 
compared with negative control siRNA transfected cells. There was a 4-fold 
decrease in genomes of progeny virus, yet at least a 20-fold decrease in viral 
tegument and glycoprotein. Additively these defects do not account for the 
consistent near 3- log10 decrease in PFU/mL observed in lysates from fibroblast 
cells after ATP6VOC knock-down, compared with negative control transfected 
cells. Taken together this indicates that there is a gross defect in viral assembly 
and egress, and that the majority of viral genomes that are egressing the cell are 
within defective particles.  
4.8.1. Possible roles of vacuole acidification in assembly 
While the data presented here demonstrate that ATP6VOC is required for VAC 
biogenesis and efficient viral replication, they do not identify the exact role of 
ATP6VOC during viral assembly and egress. It seems likely that the role of 
ATP6VOC in v-ATPase mediated acidification of endocytic and secretory 
vacuoles is likely to be central to this role. This begs the question: what role 
does acidification have within the compartments that make up the VAC? 
A characteristic feature, and key determinant, of early to late maturation of 
endosomes and secretory vesicles is the progressive acidification of these 
compartments. When v-ATPase activity is inhibited, the maturation of early 
endosomes is blocked, post translational modification of newly synthesised 
proteins is inhibited, secretory vesicles are mis-localised, and downstream 
lysosomal degradation is disrupted [269].  
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There is evidence that several HCMV miRNAs manipulate the fates of 
compartments within the endocytic and secretory pathways to facilitate VAC 
biogenesis [172]: inhibiting the maturation of early endosomes by knocking 
down Rab5; inhibiting endosomal recycling by knocking down Rab11 [270]; 
disrupting vesicular membrane anchoring and fusion by knocking down VAMP3 
and SNAP23 [271]; and preventing basolateral transport of cargo by knocking 
down CDC42 [272, 273].  
The involvement of v-ATPase activity in almost every step of the endocytic and 
secretory pathways suggests that ATP6VOC is likely to have a profound effect 
on these pathways, and this appears to be crucial for VAC biogenesis. Indeed, 
the observation that knockdown of ATP6VOC inhibits VAC biogenesis indicates 
that v-ATPase activity is required within these compartments to facilitate their 
redistribution to the VAC. Due to the diverse effects v-ATPase activity within the 
secretory and endocytic pathways, dissecting the specific roles of each of these 
activities in VAC biogenesis, and HCMV biology as a whole, will be difficult to 
ascertain. 
Beyond the biogenesis of the VAC, there are a number of plausible roles for the 
v-ATPase in the assembly of virions. The sorting of newly synthesised proteins 
emerging from the endoplasmic reticulum is dependent upon an acidic luminal 
pH within trans-golgi vacuoles, and it is likely that this machinery is subverted 
during infection to allow the virus to direct the localisation of viral proteins 
[274, 275]. Indeed, there are examples of viral glycoproteins being trafficked in 
this manner in HSV1 [276-278] and in HCMV [279]. The trans-golgi network is 
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also the site of post-translational glycosylation of newly synthesised proteins. 
This process is dependent on an acidic luminal pH within these compartments 
to facilitate the modification of substrates and this has a profound effect on the 
stability of these proteins [255, 256]. Glycosylation promotes the correct folding 
of newly synthesised proteins, and this is critical for their stability. There are 
several examples of herpes viral glycoproteins being heavily glycosylated, 
including gB, which is a key determinant of viral entry [280, 281]. gB is thought 
to be the fusion protein trigger required for HCMV cell entry, after gH/gL bind 
receptors on the cell surface [15]. gB homologues in other herpesviruses have 
the same activity, and have been shown to change their conformation in 
response to certain stimuli, including pH. This is important in their functionality 
in egress of the virus from host cells and in their subsequent entry into new host 
cells [16, 17, 282, 283]. In addition to gB, there are 6 other glycoproteins that 
have been identified as being critical in HCMV entry; gH, gL, gO, UL128, UL130, 
and UL131A. gH/gL/gO form a timer which is sufficient for entry into fibroblast 
cells and gH/gL/UL128-31 form a pentamer that is required for entry in to 
epithelial and endothelial cells. It is conceivable that the mis-folding of viral 
glycoproteins has a major effect on viral assembly and egress, as these events 
are likely to be closely intertwined. Any disruption to glycoprotein 
incorporation into progeny virus will also likely have profound effects on their 
downstream functionality in infection. 
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4.8.2. Possible roles of miR-US25-1 regulation of ATP6VOC in infection 
Based on the data presented in this chapter, there are several valid scenarios by 
which the inhibition of ATP6VOC mediated vacuolar acidification might disrupt 
VAC biogenesis and viral assembly. However, it is unclear whether these roles 
are truly reflective of miR-US25-1 regulation of ATP6VOC during infection.  
As described earlier, herpesviruses utilise a variety of mechanisms to restrict 
their own replication in order to facilitate the establishment and maintenance of 
latency. It may be that miR-US25-1 regulation of ATP6VOC during infection acts 
to restrict HCMV lytic gene expression in a similar fashion. However, the viral 
phenotype evident in fibroblast cells after transfection of ATP6VOC siRNA may 
be somewhat artificial, as it is the result of an almost complete knock-down of 
ATP6VOC. In eukaryotes, miRNAs do not typically regulate gene expression by 
causing this sort of abrupt change in transcript levels. Rather, they facilitate the 
fine-tuning of gene expression. Current evidence suggests that viral miRNAs 
likely to act in a similar fashion, 'rheostatitically' fine-tuning host-cellular and 
viral gene expression during infection. As such, the possibility that marginal 
expression of ATP6VOC may in fact facilitate lytic replication needs to be taken 
into account when considering the role of miR-US25-1 during infection.  
Restrictive roles 
It is possible that ATP6VOC down-regulation by miR-US25-1 at late time-points 
may act in infection to restrict the lytic cycle and may contribute to the 
establishment of latency in vivo. There is evidence that HCMV regulates lytic 
gene expression via the activity of miRNAs. Two independent studies have 
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demonstrated that HCMV miR-UL112-1 regulates the expression of the major 
transcriptional transactivator, IE72 [177, 284]. If the regulation of ATP6VOC by 
miR-US25-1 had a similar role in HCMV infection, it would be difficult to dissect. 
A significant hurdle is that in vitro latency models available for HCMV do not 
allow for the establishment of latent infection in lytically infected cells [84] and 
unlike EBV and KSHV miRNAs, the expression of HCMV miRNAs has not been 
observed in experimental latency. As such, it would be difficult to ascribe this 
role to miR-US25-1 regulation of ATP6VOC.  
Another possibility is that miRUS25-1 regulation of ATP6VOC might be 
important in the maintenance of latency, as seen for miRNAs expressed by KSHV 
and EBV. Again, this possibility will be difficult to dissect as the transcriptional 
status of miR-US25-1 is unknown during latency [208]. 
Enhancing roles 
There are also a variety of roles potentially attributable to ATP6VOC regulation 
that would enhance HCMV replication. The acidification of vacuoles is 
dependent on v-ATPase functionality, and therefore dependent upon ATP6VOC 
expression. Acidification is critical in the transport of exogenous material via 
the endocytic pathway, and endogenous material via the secretory pathway to 
the lysosome for degradation. Cytoplasmic macromolecules may also be 
degraded by autophagy. Autophagy is a pathway by which macromolecules in 
the cell are encased in a double membrane vesicle that fuses with the lysosome 
resulting in the contents being degraded. v-ATPase activity is likely to have a 
pivotal role within the autophagic process as acidification of the lysosome is 
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required for activation of degradative enzymes, and bafilomycin has been 
shown to be a specific inhibitor of the fusion of the autophagosome and 
lysosome [285]. Within the context of infection, inhibition of these activities 
would prevent the breakdown of viral constituents during infection. Potentially, 
this would facilitate viral assembly, and might prevent the subsequent 
trafficking of viral epitopes to the cell surface via MHC-class I and II and 
stimulation of an inflammatory response. This would be highly beneficial to the 
virus in evading the clearance of infected cells by the host cell-mediated 
immune response. There is evidence that inhibition of endosomal trafficking 
and lysosomal activity in HIV infection results in an increase in viral replication 
[286, 287] and there are an increasing number of examples of viral processes 
that directly subvert autophagy during HCMV, VZV, HSV1, and influenza A virus 
infection [288-300]. This indicates that autophagy may play an important role 
in the host immune response to virus infection. Consistent with this hypothesis, 
preliminary data from fibroblast cells transfected with ATP6VOC siRNA or a 
miR-US25-1 mimic demonstrate an accumulation of autophagy biomarker 
LC3BII within the cell, which is likely to be the result of an accumulation of 
autophagosomes. This highlights the possibility that the subversion of 
autophagy may be a role of the miRUS25-1 regulation of ATP6VOC during 
infection (personal communication, Dr Finn Grey, Roslin Institute, Edinburgh).  
There is a possibility that the apparent induction of immediate-early gene 
expression in fibroblasts after ATP6VOC knock-down may be connected with 
the inhibition of autophagy and other lysosomal degradation pathways. It is 
 167 
conceivable that endocytic and autophagic pathways might divert internalised 
virions and their components towards lysosomes for degradation, and that 
inhibiting these processes via ATP6VOC knock-down allows for more viral 
genomes to reach the nucleus, effectively altering the MOI. 
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5. Concluding remarks 
 169 
5.1. Future directions 
In the data presented in Chapters 1.9 and 2, hundreds of host-cellular targets of 
HCMV miRNAs were identified which potentially represent novel host-virus 
interactions. In future, it would be useful to expand these global analyses in 
order to improve our understanding of the HCMV miRNA 'targetome'.  
HCMV has a broad tropism in vivo, and it is likely that some host-cellular targets 
of HCMV miRNAs will be cell type specific. Within the scope of the work 
presented here, it was only possible to investigate miRNA targets in fibroblast 
cells. It is plausible that performing similar studies in other cell types, such as 
endothelial and epithelial cells would yield a distinct subset of miRNA targets 
that are important for HCMV propagation in these cell types, and this would be 
an interesting route of future study. 
It should also be noted that the in vitro model of infection in fibroblast cells only 
supports the lytic phase of the HCMV lifecycle. As such, in this study it was not 
possible to identify any targets transcripts that are specifically regulated by 
HCMV miRNAs during latent infection. There is growing evidence that miRNA 
regulation of host and viral genes in HSV-1 and 2, EBV, and KSHV infection play 
important roles during latency (see Chapter 1.8), and it would be of great 
interest to investigate these potential roles during HCMV latency, both in vitro 
and in vivo. 
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With regards to the approach used in the miRNA target screen, it would be 
interesting in future to use biochemical techniques that allow for the 
identification of transcripts that are rapidly degraded, or those that do not form 
stable interactions with RISC. While RISC-IP is clearly a powerful tool in 
identifying the targets of viral miRNAs, cutting-edge techniques such as CLASH 
allow for the identification of not only the target transcript, but the miRNA 
responsible, and the target site with the transcript. This information would be of 
great benefit to viral miRNA researchers, would make target validation more 
straight-forward, and has the potential to dramatically advance our 
understanding of viral miRNA targets in the near future. 
With regards to the siRNA screen of HCMV miRNA targets, it is likely that 
several genes that play crucial roles were discounted due to an apparent lack of 
effect on viral replication based on the criteria that were used for establishing a 
viral phenotype. The true role of these genes may have been masked within the 
siRNA screen due to redundant co-factors, tropism specific roles, or effects that 
don't impact viral replication as monitored by GFP expression in TB40E infected 
cells. To circumvent these possibilities, it would be of interest in future to 
screen progeny virus from cells transfected with these siRNAs for the capacity 
to infect naive cells. Indeed, observations from others who have used this 
technique for screening endocytic pathway genes have demonstrated that the 
knock-down of certain genes can cause a dramatic decrease in progeny viral 
fitness, while having no effect on viral replication as monitored by GFP 
(personal communication, Dr. Oliver Lin, Roslin Institute, Edinburgh). There is 
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also a likelihood that the critical role of the regulation of some genes in HCMV 
biology may only become apparent after their over-expression, and this is 
particularly relevant with regards to regulation by miRNAs. As such it would be 
of interest to develop a lenti-viral library for the over-expression of miRNA 
target genes in order to better understand the effect of their regulation during 
infection. 
Finally, in addition to ATP6VOC several other potentially interesting targets of 
HCMV miR-US25-1 were identified in this study; CCNE2, BCKDHA, and LGALS3. 
While these genes were not selected for further characterisation based on the 
results of the siRNA screen, they may still have a crucial role in HCMV biology. 
With possible roles in cell cycle manipulation, autophagy, and mTOR signaling, 
each represents a potentially interesting avenue of future research. 
This study demonstrated that miR-US25-1 is the sole miRNA responsible for 
regulating several host cellular genes during infection, and identified ATP6VOC 
as a critical host factor in HCMV VAC biogenesis and assembly. However, it 
stopped short of identifying the specific role of miR-US25-1 regulation of 
ATP6VOC during infection. Clearly this would be an interesting avenue of future 
research, and the work presented here is a prelude to ongoing studies to 
establish these roles. As discussed in Chapter 4, the potential subjugation of 
autophagy by miR-US25-1 during infection, and the possible effect of this on the 
immune response to HCMV may be of particular interest in this regard.  
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5.2. Conclusions 
In this study, hundreds of host-cellular transcripts were identified as being 
potentially regulated by HCMV encoded miRNAs during lytic infection. Using a 
combination of bioinformatics and further biochemical techniques, the 
regulation of 13 host cellular-transcripts by HCMV miRNAs were independently 
validated, and miR-US25-1 was identified as the sole HCMV miRNA responsible 
for the regulation of ATP6VOC, BCKDHA, CCNE2, and LGALS3 at the RNA and 
protein level during infection. The regulation of each of these genes by 
miR-US25-1 represent novel-host virus interactions, which the exception of 
CCNE2 which was identified as a prelude to the work presented here [165]. As a 
first step to ascertaining the roles that these genes play in HCMV biology a 
phenotypic screen was performed, and this identified ATP6VOC as a critical 
factor that is required for HCMV replication in vitro. ATP6VOC was subsequently 
shown to be critical in the formation of the HCMV VAC, the failure of which has 
repercussions on the formation of progeny virus. The disruptive effect of 
ATP6VOC knock-down on the formation of the HCMV VAC is likely the result of 
the inhibition of v-ATPase induced acidification of host-cell secretory and 
endocytic vacuoles. 
In conclusion, this work has greatly increased the number of validated host-
cellular HCMV miRNA targets that have been identified to date, and this acts as a 
platform to achieve a better understanding of the role of HCMV miRNA 
regulation of host-cellular gene expression during infection. Improving our 
understanding of the complex virus-host interactions that take place during 
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HCMV infection will be critical in future as we look forward to developing novel 
therapeutics to tackle this clinically important human pathogen. 
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6. Materials and Methods 
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6.1. General Methods 
6.1.1. Cell lines and culture 
Human primary normal human dermal fibroblast cells (NHDF) (Clonetics), and 
human embryonic kidney 293 (HEK 293) cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum 
(FCS) and penicillin-streptomycin-L-glutamine (PSG), and incubated at 37°C in 
5% CO2. 
6.1.2. Virus strains 
Wild type AD169 was obtained from the American Type Culture Collection 
(Rockville, MD). BAC derived AD169 pAD CRE was provided by Thomas Shenk 
[209]. TRTF was provided by Professor Jay Nelson and TB40E BAC4 eGFP was 
provided by Felicia Goodrum [47, 301]. Purified virus was generated as follows: 
Sub-confluent NHDFs were infected at low MOI. Infected cells were scraped into 
media at 168 hpi and dounced. Cellular debris was cleared from the supernatant 
by low speed centrifugation (2000 g for 30 minutes). Purified virus was 
obtained from infected supernatant by ultracentrifugation over a 20% sorbitol 
cushion (40000 g for 1 hour). Purified virus was re-suspended in DMEM 
containing 10% FCS, and stored at -80°C.  
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6.2. Chapter 1 methods 
6.2.1. RISC-IP and microarray 
RISC-IP analysis was performed as described in [139]. NHDFs were seeded to a 
density of 80% in tissue culture grade 10 cm dishes. Cells were infected at a MOI 
of 3 with AD169 or TR HCMV strains. Media was removed from the cells, cells 
were washed twice with PBS, and harvested into 1 mL of lysis buffer (20 mM 
Tris pH7.5, 2.5 mM MgCl2, 200 mM NaCl, 0.05% Nonidet P40, 1mM DTT, 1x 
proteinase inhibitor, 1:50 RNasin 40 U/ μL. Lysates were vortexed, and 
centrifuged at 12000 g for 15 minutes at 4°C. 50 μL of lysate was added to 
500 μL of Trizol® reagent for total RNA. 
25 μL of protein-A sepharose (for Ago-2 antibody pull-down), streptavidin-agar 
(for biotin pull-down) or myc-ago (for myc-Ago pull-down) beads were 
prepared in advance. Beads were pelleted (1000 g), washed in lysis buffer 
(without RNasin), and re-suspended to a final volume of 100 μL per sample. 
Beads were blocked with 100 mg tRNA and 100 mg BSA for 2 hours at 4°C, and 
washed twice in 300 μL lysis buffer (without RNasin). Beads were resuspended 
to a final volume of 100 μL per sample. 
For myc and biotin pull-downs, lysates were added straight onto the blocked 
beads. For antibody pull-downs, lysate fractions were incubated with Ago-2 
antibody or with pre-bleed serum for 1 hour at 4°C. Lysates were then 
incubated with beads for 2 hours at 4°C. Beads were pelleted (1000 g), and 
washed twice with 500 μL of lysis buffer. Beads were then resuspended in  
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500 μL Trizol® reagent. RNA fractions were isolated according to the 
manufacturer’s instructions (www.lifetechnologies.com/trizol). 
Ago-2 specific antibody was generated by immunisation of rabbits with a 
peptide corresponding to the N-terminal region of Argonaute-2 
(5-MYSGAGPALAPPAPPPPIQGYAFKPPPRPD-3’). 
RNA samples were analyzed for quality using Agilent Bioanalyser. Transcript 
levels were determined using the Illumina HumanRef-8 microarray platform. 
6.2.2. Bioinformatic analyses 
HCMV miRNA targets sites within host-cellular genes were ascertained by 
scanning 5'UTR, ORF, and 3'UTR sequences (obtained from 
www.ncbi.nlm.nih.gov) for target sites of HCMV miRNAs (obtained from 
www.mirbase.org) using the RNA-hybrid online tool (bibiserv.techfak.uni-
bielefeld.de/rnahybrid). Parameters were selected to include Watson-Crick 
base pairing between nucleotides 1 to 7 or 2 to 8. 
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6.3. Chapter 2 methods 
6.3.1. RISC-IP 
RISC-IPs were performed and RNA isolated as described in Chapter 6.2.1. RNA 
was quantified by spectrophotometer, and 200ng was reverse-transcribed, 
using the high capacity cDNA reverse transcription kit and poly-dT primers 
according to the manufacturer’s instructions (Life Technologies). This cDNA 
was then used for subsequent qRTPCR analyses.  
The efficacy of RISC-IP was assessed using primer-probe qRTPCR against 
SOCS1, a transcript that is readily regulated by host-cellular miRNAs, and as 
such was enriched equivalently in each RISC-IP sample, infected and uninfected. 
6.3.2. miRNA and siRNA transfections 
miRNAs and siRNAs were transfected into NHDF or HEK 293 cells using 
lipofectamine RNAiMax® reagent according to the manufacturer’s instructions 
(Life Technologies). For NHDFs and HEK 293s, cells were seeded to 60-80% 
confluence and transfected with 20 nM siRNA or miRNA mimic in Optimem® 
serum free medium (Life Technologies). NHDFs were double transfected a 
minimum of 6 hours apart, and HEK 293s were single transfected. 
6.3.3. qRTPCR 
Validated primer probe assays were selected for best coverage from Life 
Technologies. qRTPCR was carried out using Taqman® gene specific primer 
probe sets (Life Technologies) on a Rotor gene 3000 thermal cycler (Corbet 
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Research). The thermal cycler was programmed as follows: 1x HOLD; 2 minutes 
at 50°C; 1x HOLD 10 minutes at 95°C; 40x CYCLE 15 seconds at 95°C, 1 minute 
at 60°C. Fluorescent signal acquisition occurred after each cycle at the required 
wavelengths. For more information see: 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/g
eneraldocuments/cms_042996.pdf. 
Relative gene expression levels were ascertained using the ΔΔct method. 
Statistical significance was analysed using Mann Whitney U-test. The calculative 
method can be found in Table 7.4. An arbitrary significance threshold of 0.01 
was used. 
Table 6.1 qRTPCR primer probe assays 
   
Assay ID Accession No. Source 
ATP6VOC Hs00798308_sH Life technology 
BCKDHA Hs00958109_m1 Life technology 
CCNE2 Hs00180319_m1 Life technology 
LGALS3 Hs00173587_m1 Life technology 
NUCB2 Hs00172851_m1 Life technology 
SGSH Hs00164924_m1 Life technology 
CCNE1 Hs01026536_m1 Life technology 
BSG Hs00936295_m1 Life technology 
PIGH Hs00762253_s1 Life technology 
LEPRE1 Hs00223565_m1 Life technology 
NUCB1 Hs00939167_m1 Life technology 
LIN28B Hs01013729_m1 Life technology 
GRN Hs00963707_g1 Life technology 
COMMD10 Hs00211680_m1 Life technology 
ACTB Hs01060665_g1 Life technology 
SOCS1 Hs00705164_s1 Life technology 
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6.3.4. Western blot analysis 
Protein lysates were obtained from NHDFs infected with either AD169, AD169 
25-1/2KO, mock infected NHDFs, or NHDFs transfected with specific siRNAs as 
negative controls for protein expression. NHDF for infection were seeded at a 
density of 1x106 cells in 100 mm2 tissue culture coated dishes and 24h later 
were infected at an MOI of 3. At 72 hpi the media was removed, cells were 
washed twice with PBS, and protein lysates were harvested in 1 mL of 2X 
laemmli buffer (BioRad). NHDFs for transfection were seeded at 60-80% 
confluence, 4x104 cells per 24 well. NHDFs were double transfected as 
described previously, and protein lysates harvested at 72 hours post 
transfection in 65 μL 2X laemmli buffer (BioRad).  
For the majority of proteins, PAGE separation was performed on 4-12% Mini-
Protean TGX® pre-cast gradient gels (BioRad), using 1X Tris-Glycine SDS 
running buffer (0.025M, 0.192M, 0.1%, respectively). ATP6VOC PAGE 
separation was performed on 12% Novex® pre cast gel (Life technologies) using 
a dedicated MES running buffer, due to it's small size (16 kda). 30 μL of each 
sample was loaded, and PAGE gels were run at 150 V until the dye front exited 
the gel. PAGE gels were blotted onto either nitrocellulose (pore size of 45 
micron with the exception of ATP6VOC, which required pore size of 20 micron) 
were wet transferred in 1X Tris-Glycine transfer buffer with 20% methanol on 
ice at 100 V for 1 hr. Protein size was ascertained using 10-250 kd pre-stained 
protein marker (Life technologies). 
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Membranes were blocked for 1 hour at room temperature using 1X ECL 
advanced blocking reagent (Amersham). Primary antibodies were diluted 
appropriately and left to hybridise with membranes for 12 hours at 4°C. 
Membranes were then washed twice in 1X PBS-Tween 1% three times for 20 
minutes. Secondary fluorescent antibodies (IR800 or IR680 dye conjugated 
anti-rabbit IgG or anti-mouse IgG secondary antibodies from LiCOR®) were 
diluted 1:1000 in 1X PBS-Tween 1%, and left to hybridise with membranes in 
the dark for 45 minutes at room temperature. Membranes were washed three 
times for 5 minutes before fluorescent image acquisition. 
Membranes were imaged using infrared fluorescence and quantified using 
LiCOR® Odyssey scanner and software. 
Table 6.2 List of primary antibodies and dilutions for western blot 
analysis 
      
Gene ID Species Lot no. Accession 
No. 
Dilution  Supplier 






































 ab9485 1 in 10000 Abcam 
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6.3.5. Luciferase assay 
The region containing the predicted miR-US25-1 target site (GAGCGGT starting 
at nucleotide 186) within the ATP6V0C ORF was created using custom 
oligonucleotides (146-226 nucleotides downstream of the ATG). For the 
ATP6V0C seed mutant construct, nucleotides 186-191 were replaced with a 
BAMHI restriction site. Inserts were cloned downstream of the renilla luciferase 
reporter gene in the pSicheck 2® dual luciferase construct (Promega).  
BCKDHA, CCNE2, LGALS3, NUCB2, and SGSH 5'UTR regions were amplified by 
PCR from genomic DNA. The primers used to clone these regions and the length 
of amplicons are shown in Figure 6.1. These amplicons were cloned upstream of 
the firefly luciferase reporter gene in the pGL4 luc2® construct (Promega). The 
pRL® renilla luciferase construct (Promega) was used as a control. 
For luciferase assay, HEK-293 cells were seeded at 60-80% confluence in 96 
well tissue culture coated plates. Luciferase constructs (200 ng) were co-
transfected with miR-US25-1 seed mutant mimic (20 nM), miR US25-1 mimic 
(20 nM) (both IDT) or negative control siRNA mimic (Qiagen) using 
Lipofectamine 2000 reagent in accordance with the manufacturer’s instructions 
(Life technologies). At 48 hours post transfection, cells lysate were harvested, 
and luciferase levels analysed using luciferase Dual-Glo® reagents and a GloMax 
plate reader (Promega). 
A schematic representation of the predicted target sites that were cloned into 
luciferase constructs for each of these genes is provide in Figure 6.1. 
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Figure 6.1 Schematic representation of the bioinformatically predicted target sites for ATP6VOC, BCKDHA, CCNE2, 
LGALS2, NUCB2, and SGSH 
ORFs are designated in red, with 5’ and 3’ UTRs designated in green. Blown up regions show individual miR-US25-1 targets sites 
and predicted miRNA binding according to RNA hybrid. 
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6.3.6. Mutant virus strains 
miR-US25-1/2 pre-miRNA coding region was deleted from AD169 pAD CRE BAC 
clone using BAC technology as previously described [302]. A PCR amplified 
cassette containing FRT flanked kanamycin was recombined into AD169 BAC 
genome replacing the miR-US25-1 coding region using primers listed below.  
Table 6.4 Primer sequences for BAC mutagenesis 
 
Primer  Sequence 
miR-US25-1 KO forward GACGTCGGGACCGACGGACGCGACTCGGGGTCCT
TCGGTTCAGGAACACTTAACGGCTGA 
miR-US25-1 KO reverse ACCGACCTAGCGTTCGGACCGGTGCGCAGAAACA
GCCGGCGAAAAGTGCCACCTGCAGAT 
miR-US25-2 KO reverse TCGAACGTCTCTCCGGTAACTATCGGCGGCCGGG
GCTGTGCAGGAACACTTAACGGCTGA  
  
Sequence in italics indicate regions homologous to an FRT flanked Kanamycin 
cassette, with the remaining sequence homologous to recombination sites 
within the HCMV genome. The Kanamycin cassette was then removed by 
recombining the FRT sites through inducible FLIP recombinase. The resulting 
BAC was isolated and electroporated into NHDFs, which were then propagated 
to produce infectious virus.
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Figure 6.2 Schematic representation of AD169 miR-US25-1 knock-out virus cloning strategies 
US25-1 and US25-2 pre-miRNA coding sequences are designated by the red arrows. Homologous flanking regions are designated 
by the red blocks. 
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6.4. Chapter 3 methods 
6.4.1. siRNA transfections and GFP plate reading 
For TB40E GFP expression analyses, NHDFs were seeded at 60-80% confluence 
in 96 well and double transfected as previously described. At 72 hours post 
transfection, cells were with TB40E at an MOI of 1. At 24 hpi, the infectious 
inoculum was removed, and cells were washed three times with PBS. Cells were 
then overlaid with phenol red free DMEM, and eGFP monitored using a Biotech 
Synergy HT plate reader (excitation 485 nm: emission 525 nm).  
siRNA details for miR-US25-1 targets and for miRNA mimics are provided in 
Table 6.5.  
The screen of the top 30 miRNA targets was performed using pre-validated 
Silencer Select® (Life Technologies) siRNAs. Assay IDs, accession numbers, and 
target sites are provided in Table 6.6. 
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Table 6.5 List of miR-US25-1 target siRNA mimic sequences 
   
Gene ID Accession No. Sense 
Negative Control 1027310 UUCUCCGAACGUGUCACGUdTdT 
ATP6V0C S80 S80 ACUGGAUGUUUAUUUAUAATT 
ATP6V0C stealth 1 HSS141330(3 GCCTATGGCACAGCCAAGAGCGGTA 
ATP6V0C stealth 2 HSS141332(3 TCGTCGCCCTCATCCTCTCCACAAA 
ATP6V0C stealth 3 HSS182300 CGGAGCAGATCATGAAGTCCATCAT 
ATP6V1A s1791 GGUAAGGUAGAGUCAAUUATT 
ATP6V1H s28403 GGCUAUGAUUCAGUGCAAATT 
BCKDHA s1909 UGACACUGCUUAACACCAUTT 
CCNE2 s17449 CCAUUGAAGUGGUUAAGAATT 
LGALS3 s8148 GGAGAGUCAUUGUUUGCAATT 
NUCB2 s9773 GGAUUCCCUUCAAGAUAUATT 




  GAGAGUGGCGCGUACAACA 
  CGGAACAUCACUAGAAUUA 
  ACAAGGACCUCCGUCAUUA 
US25-1  AACCGCUCAGUGGCUCGGACCGC 
US25-1mut  AAGGAUCCAGUGGCUCGGACCGC 
US25-2-3p  GCGGGAGCUCUCCAAGUGGCUAG 
US25-2-5p  AGCGGUCUGUUCAGGUGGAUGA 
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Table 6.6 List of siRNAs for putative targets of HCMV miRNAs 
   
Gene ID Accession No. Primary NCBI Refseq siRNA 
target nucleotide location 
ACP2 s930 451 
ATP1A3 s1724 230 
ATP6VOC s79 892 
BCKDHA s1909 373 
BSG s194316 2055 
C1ORF35 s35664 1229 
CCNE1 s2524 1052 
CCNE2 s17449 1029 
COL1A1 s375 343 
CTRB2 s196535 795 
DSC2 s4309 3062 
FAC1 s197300 1452 
FAM38 s226181 4296 
FLJ39061 s46554 509 
GRN s6149 552 
KRTAP107 s196174 1063 
LEPRE1 s34536 1054 
LGALS3 s8148 599 
LIN28B s52477 612 
NUCB1 s9770 1659 
NUCB2 s9773 619 
PD1A5 n313465 1842 
PIGH 117257 544 
PRSS8 s11273 1079 
SGSH s12778 479 
SPRB s13378 158 
STX10 137195 409 
TMEM74 s45992 590 
 
6.4.2. Cell viability analysis 
NHDFs were seeded at 60-80% confluence double transfected with ATP6VOC 
siRNAs or negative control siRNA using Lipofectamine RNAimax in accordance 
with the manufacturer’s recommendations. Cell viability was assessed using Cell 
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Titer-Glo® luminescent cell viability assay (Promega) in accordance with the 
manufacturer's instructions. 
6.4.3. Viral plaque analysis 
Viral plaque analyses were performed as described in [303]. NHDFs were 
transfected as previously described. At 72 hours post transfection, cells were 
infected at an MOI of 1. At 24 hpi, cells were washed three times with PBS and 
overlaid with fresh media. Infected cells were harvested, scraped into media, at 
24 hpi, and at every subsequent 24 hour time-point. Samples were snap frozen 
at -80°C to lyse the cells. These lysates were then serially diluted, and used to 
infect sub-confluent NHDFs. At 24 hpi, cells were overlaid with 0.5% 
carboxymethyl-cellulose (CMC) diluted in DMEM +10% FBS+PSG. At 168 hpi, 
the CMC was removed, monolayers were stained with toluidine blue, and 
plaques counted. 
6.4.4. Viral genome copy analysis 
Infected cells were harvested at designated time-points and applied to DNEasy® 
blood and tissue kit columns (Qiagen). DNA was extracted following the 
manufacturer's protocol. 
6.4.5. qRTPCR 
Specific primer and probe sequences were kindly provided by Lauren Hook. 
IE86, UL83 and gH primer and probes were synthesised by Life Technologies. 
Sequences are provided in Table 6.7. 
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Table 6.7 List of primer and probe sequences for viral genes 
    

























TGTGTAC / FAM 
GGATGTTCAGC
ATCTTGAGCG 
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6.5. Chapter 4 methods 
6.5.1. Immunofluorescence and confocal microscopy 
Round glass 14mm cover slips were sterilised and placed in a tissue culture 
coated 24-well plate. NHDFs were seeded for siRNA transfection, and double-
transfected as previously described. At 72 hours post transfection, cells were 
infected with AD169 at an MOI of 1. At 144 hpi, cover slips were washed with 
PBS, and fixed for 15 minutes with freshly prepared 4% paraformaldehyde in 
Dulbecco's PBS (DPBS). Coverslips were then washed 3 times with DPBS. 
Coverslips were then permeabilised for 5 minutes (DPBS + 3% FBS + 0.2% 
TX100), and then washed 3 times with DPBS + 3%FBS. Coverslips were then 
blocked for 1 hour at room temperature (DPBS + 3% FBS + 0.5% Tween 20), 
before the addition of primary antibodies, diluted as specified in Table 6.8. 
Coverslips were incubated with primary antibodies overnight at 4°C. Coverslips 
were washed 3 times with DPBS + 3% FBS before the addition of secondary 
fluorescent antibodies (AlexaFluor® anti-mouse 647 and anti-rabbit 488 [Life 
Technologies]). Coverslips were incubated for 1 hour at room temperature, and 
washed 3 times with DPBS+3% FBS. Finally, coverslips were nuclear stained 
using 1:1000 DAPI before mounting to slides using 5 μL Prolong Gold® anti-fade 
reagent (Life Technologies). 
Images were acquired using a Zeiss LSM 710 confocal microscope in accordance 
with the manufacturer's instructions. Images were compiled and analysed using 
Fiji open source image processing software (http://www.fiji.sc). 
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6.5.2. Supernatant and cell associated virus purification 
AD169 was propagated as previously described. Cells were scraped into 
infected supernatant at 7 days post infection. Cell associated virus was isolated 
from the supernatant by centrifugation (1000 x g for 1 hour). Supernatant was 
removed from the cell pellet. Virus was then pelleted from the supernatant by 
ultra-centrifugation following the method outlined previously. Supernatant 
purified virus was then re-suspended in DPBS. Fractions of purified virus were 
then added to either DMEM for plaque analysis, laemmli buffer for western blot 
analysis, or added directly to DNEasy blood and tissue DNA isolation columns 
(Qiagen). Plaque and western blot analyses were then performed as previously 
outlined, and viral DNA was isolated in accordance the manufacturer’s 
instructions. Viral DNA was assayed using the gH primer probe assay (Table 
6.7), and relative copy number calculated using the ΔΔct method. 
6.5.3. Western blot analyses 
Western blot analyses were performed as previously outlined, using Novex 
4-12% and MOPS running buffer. Primary antibodies and dilution for western 
blot are shown in Table 6.8. 
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Table 6.8 Antibodies for immunofluorescence microscopy and western 
blot 
 
Gene ID Species Accession No. Dilution  Supplier 
TGN46 Rabbit  PA5-23068 1:500 IF 
1:1000 WB 
Pierce 
EEA1 Rabbit ab2900 1:500 IF 
1:1000 WB 
Abcam 
pp28 Mouse CH19 1:500 IF 
1:1000 WB 
Santa Cruz 
gB Mouse 2F12 1:1000 WB Abcam 
IE72/86 Mouse  1:2000 WB  
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7.1. Appendix I: Supplemental Data 
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Figure 7.1 siRNA screen: GFP intensity in fibroblast cells transfected with siRNAs against the top 30 host-cellular targets 
of HCMV miRNAs (20 nM) (N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection were infected with TB40E. Virus replication was 



























Figure 7.2 siRNA screen: GFP intensity in fibroblast cells transfected with siRNAs against the top 30 host-cellular targets 
of HCMV miRNAs (20 nM) (N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection were infected with TB40E. Virus replication was 




























Figure 7.3 siRNA screen: GFP intensity in fibroblast cells transfected with siRNAs against the top 30 host-cellular targets 
of HCMV miRNAs (20 nM) (N=3) 
Fibroblast cells were transfected with siRNAs and 72 hours post transfection were infected with TB40E. Virus replication was 




























Figure 7.4 IFN-β expression in fibroblast cells transfected with pooled 
ATP6VOC siRNA (20 nM) (N=1) 
Fibroblast cells were transfected with ATP6VOC, Negative control siRNA, or a 
IFNb positive control siRNA. 72 hour post transfection, RNA was extracted and 




Figure 7.5 Cell viability in fibroblast cells transfected with pooled 
ATP6VOC siRNA (20 nM) (N=3) 
Fibroblast cells were transfected with ATP6VOC, or a Negative control siRNA. 
72 hour post transfection, cells were lysed and cell viability measured using a 








































7.2. Appendix 2: List and description of electronic supplemental data 
Table 7.1 Microarray dataset from RISC-IP of AD169 infected fibroblast 
cells 
 
Table 7.2 Microarray dataset from RISC-IP of TR infected fibroblast 
cells 
 
Table 7.3 Microarray from RISCIP in pUS25-1 and b-US25-1 transfected 
HEK 293 cells 
 
Table 7.4 Raw data from RISC-IP and qRTPCR in fibroblasts infected 
with AD169, AD169 miR-US25-1KO, AD169 miR-US25-1/2KO, and 
uninfected fibroblast cells 
 
Table 7.5 RNA hybrid target prediction data for miR-US25-1 targeting 
 
Figure 7.6 3D renders of VAC in fibroblast cells after ATP6VOC knock-
down compared with negative control siRNA transfected fibroblast cells 
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7.3. Appendix 3: Publications, conference presentations, and posters 
Oral Presentations 
2013 - Society for general microbiology annual meeting, Manchester UK 
2013 - International Herpesvirus Workshop, Grand Rapids, Michigan, USA 
2014 - Society for general microbiology annual meeting, Liverpool, UK 
Poster Presentations 
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